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ABSTRACT

Glaucoma is a neurodegenerative protein misfolding disorder classified by
increases in IOP, damage to retinal ganglion cells (RGCs), optic nerve (ON) head
damage, and progressive irreversible blindness. Primary open-angle glaucoma (POAG)
is the most common form of glaucoma, constituting over 90% of clinical cases. POAG is
observed in patients where normal outflow channels, mainly the trabecular meshwork
(TM), are exposed at the angle formed by the iris and cornea. However, due to TM
cellular dysfunction, aqueous outflow resistance is increased preventing normal
circulation of aqueous humor. Recent studies have shown that in 2-4% of POAG cases,
increased intracellular levels of a secreted glycoprotein, called myocilin, are present in
the TM.
Myocilin is a 504aa glycoprotein, with an unknown precise function. Recent
studies have postulated the importance of myocilin in oligodendrocyte differentiation,
axonal myelination, and early apoptosis of retinal cells in development, but exact
function is still widely debated. However, it is important to note that pathology
associated with myocilin is only seen during POAG. Also, only cells of the TM exhibit
toxicity when overexpressing mutant myocilin. In the normal eye, myocilin is secreted
from the ER of TM cells, however, mutations in the MYOC gene lead to an aggregationprone form of the protein, which is inefficiently processed and degraded from the ER,
leading to build-up and associated toxicity. There are over 70 known MYOC mutations
vii

associated with glaucoma, with over 90% occurring in the C-terminal OLF domain.
Some of the more common, pathological mutations are: I477N, Y437H, P370L, W286R,
N480K. All of these mutations have been observed in patients with glaucoma, and all
lead to build-up and aggregation of the mutant protein within the ER of TM cells.
Recently, work out of our lab has discovered an interaction between mutant
forms of myocilin and the chaperone Grp94. Grp94 is the resident Hsp90 isoform of the
ER. Grp94 is an important chaperone in ER quality control, aiding in the output of
properly folded secretory and membrane-bound proteins. Besides protein folding, other
roles of Grp94 in the ER include: calcium buffering, roles in ER quality control (including
targeting misfolded proteins for ERAD), peptide binding, and roles in ER stress.
Generally, terminally misfolded proteins in the ER are degraded through ERAD; the
Grp94 mediated shuttling of misfolded proteins to the ER trans-membrane machinery
for ubiquitination and subsequent translocation to the cytosol for proteasomal
degradation. However, in the case of POAG, ERAD is inefficient in mutant myocilin
degradation, causing protein accumulation within the ER.
In this study, we demonstrate that specific Grp94 inhibition of interaction with
mutant or misfolded myocilin leads to myocilin degradation and subsequent lowering of
protein accumulation in the TM, thus reducing downfield pathology associated with
POAG. Grp94 preserves mutant myocilin in the ER of TM cells leading to protein
accumulation and aggregation precipitating TM cellular dysfunction. We showed in
various in vitro cell assays that Grp94 inhibition leads to a reduction in intracellular
protein levels, while alleviating TM cellular toxicity. Furthermore, in the Tg-MYOCY437H
mouse model of POAG, we showed that topical ocular administration of a specific
viii

Grp94 inhibitor alleviated glaucomatous pathologies, including elevated IOP, myocilin
accumulation in the TM, reduced scotopic/photopic visual responses, and RGC health
and viability. Finally, we have proven the importance of ER-stress pathway malfunction
in the development of POAG pathology, while also discovering the involvement of the
autophagy mechanism for myocilin degradation following Grp94 inhibition.
Overall, this work proves that Grp94 is an important regulator of myocilin
pathology during POAG. While there are no current therapeutics on the market that
directly target the underlying POAG disease mechanism, specific Grp94 inhibition
shows great promise and should be considered for human clinical trials. If successful,
specific targeted Grp94 inhibition could be the first curative therapeutic options for
patients suffering from myocilin-associated POAG.
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Chapter One1:
Determining the client-chaperone relationship between Myocilin and Grp94
during Primary Open-Angle Glaucoma

1.1 Abstract
Endoplasmic Reticulum-Associated Degradation (ERAD) is the traditional method for
clearing and degrading misfolded proteins in the ER. This process involves the
ubiquitination and translocation of misfolded proteins through the ER lumen to the
cytosol for proteasomal degradation. A network of ER-associated chaperone proteins
aid in this translocation, and are responsible for recognition of terminally misfolded
proteins. In this work, we investigated whether the glaucoma-associated protein,
myocilin, was processed through ERAD. Myocilin is a secretory protein that is normally
transported through the ER-Golgi network, however, inherited genetic mutations in the
MYOC gene lead to a protein product that readily misfolds and accumulates in the ER
of trabecular meshwork (TM) cells. This protein accumulation precipitates cellular
dysfunction and toxicity, ultimately leading to ER stress induced TM cell death. Using
siRNA knockdown, we discovered that glucose-regulated protein 94 (Grp94), the ERassociated homolog of heat shock protein 90 (Hsp90), directly recognizes and
associates with mutant forms of myocilin. This recognition prevents normal ERAD, and
leads to intra-ER mutant myocilin protein accumulation. Additionally, through genetic

1

Portions of this work were previously published (Suntharalingam A et al, 2012) and are used
with the permission of the publisher

1

manipulation, or therapeutic intervention, inhibition of Grp94 association with mutant
myocilin led to intracellular clearance by autophagy, a robust degradation pathway for
aggregation-prone proteins. This work suggests that therapeutic interventions,
preventing Grp94 association with mutant myocilin, could be a viable option for patients
suffering from cases of myocilin-associated glaucoma.

1.2 Introduction
Primary open-angle glaucoma (POAG) is a hereditary form of glaucoma closely
linked to accumulation of the secretory protein, myocilin. Over 10% of juvenile-onset
open angle glaucoma (JOAG) and 5% of adult-onset open angle glaucoma are
associated with myocilin accumulation [1, 2]. Interestingly, although myocilin is a
ubiquitous protein, the only disease-associated pathology caused by the protein
appears to be related to trabecular meshwork (TM) cell dysfunction during POAG [3].
The trabecular meshwork is a specialized tissue network in the anterior chamber of the
eye responsible for regulating the outflow of aqueous humor. TM cell dysfunction leads
to aqueous humor outflow dysregulation causing elevated intraocular pressure (IOP).
IOP elevation is a major pathological hallmark of POAG, leading to retinal cell
dysfunction and irreversible blindness [4].
Recent studies have shown that mutations in the MYOC gene, encoding the
myocilin protein, lead to a protein product that accumulates in the endoplasmic
reticulum (ER) of TM cells [5-9]. Mutant myocilin accumulation in the ER of TM cells
leads to ER-associated cellular stress causing TM tissue network dysfunction and the
known glaucoma phenotypes [10]. Interestingly, individuals with missense MYOC
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mutations preventing the translation of myocilin [11], as well as myocilin knock-out mice
[12] do not develop glaucomatous pathologies, classifying POAG pathology as a toxic
gain-of-function. To date, over 70 MYOC mutations have been documented to be
associated with POAG pathology, with a majority occurring in the C-terminal
olfactomedin domain [13]. Mutant myocilin products have also been shown to readily
aggregate, through presence of detergent insoluble protein species, forming aggregate
species containing amyloid fibrils [14, 15].
Previous myocilin-associated glaucoma research has centered on the
development of therapeutics to alleviate protein aggregate toxicity by promoting
myocilin secretion [7, 16-18]. Unfortunately, it is still not understood why, unlike other
ER-associated mutant proteins, myocilin is inefficiently cleared through ER-associated
degradation (ERAD). In the normal cell environment, terminally misfolded intra-ER
proteins are chaperoned to the ER lumen where they are ubiquitinated and translocated
to the cell cytosol for proteasomal degradation [19]. However, this process seems to be
inadequate for degrading mutant myocilin protein. In the ER, chaperone proteins are
responsible for the recognition of misfolded proteins and determining terminally
misfolded proteins fate. Main intra-ER chaperones include glucose-regulated protein 94
(Grp94), the ER-associated heat shock protein 90 (Hsp90), and glucose-regulated
protein 78 (Grp78), an ER-associated member of the heat shock protein 70 (Hsp70)
family, also referred to as BiP. While exact intra-ER chaperone-client relationships are
still incomplete, studies have shown that both Grp94 and Grp78 associate with mutant
myocilin, although Grp94 seems to be more selective in its client determination [16, 20].
Interestingly, the significance of these chaperone associations with mutant myocilin still
3

remain unknown. Therefore, a more concise understanding of mutant myocilin
mechanics during ER accumulation could lead to viable treatment options to reduce
mutant myocilin accumulation by utilizing the ER quality-control machinery.
In this work, we set to determine the molecular relationship between myocilin and
the intra-ER chaperone network, and show the importance of Grp94 in mutant myocilin
accumulation and degradation. Mutations in the MYOC gene facilitate the interaction
between mutant myocilin and Grp94, leading to inefficient protein clearance via ERAD,
precipitating TM cellular dysfunction and glaucomatous pathology. By inhibiting the
interaction between Grp94 and mutant myocilin, whether through genetic manipulation
or pharmacological inhibition, mutant myocilin is effectively cleared and degraded
through an autophagic mechanism. Inhibiting Grp94 association with myocilin could
represent a viable therapeutic target for myocilin-associated glaucoma treatment.

1.3 Grp94 interacts with mutant myocilin, preserving it in the ER.
It is well documented that biologically, properly folded myocilin is a secreted
protein [8, 21]. Alternatively, studies have shown that mutations in the myocilin gene
lead to intracellular accumulation [22-24]. Therefore, in order to properly study myocilin
mechanics, physiologically relevant cell models must be utilized. For this, our group
developed and tested stably-transfected tetracycline-inducible cells, expressing WT and
I477N mutant myocilin. If these cells were to represent normal bodily function, one
would expect WT myocilin to be heavily secreted, while mutant myocilin to accumulate
intracellularly. To validate these cell models, we performed western blot analysis of
intracellular protein levels, and dot-blot analysis of secreted protein. We observed that
4

in cells stably overexpressing WT myocilin, all of the protein was secreted, with no
myocilin observed intracellularly. Alternatively, in cells overexpressing mutant I477N
myocilin, all of the protein was observed intracellularly, with none being secreted (Fig
1.1A). Additionally, we performed immunofluorescent co-localization studies on our cells
stably overexpressing mutant I477N myocilin, to determine if the intracellular myocilin
was accumulating within the ER. To do this, we stained for myocilin and calnexin, an ER
marker, and observed co-localization. We found that intracellular mutant myocilin colocalized with calnexin, showing that mutant myocilin was accumulating within the ER
(Fig 1.1B). Together, this data proved that our stably over-expressing myocilin cell
models emulated physiological function, where WT myocilin was heavily secreted, while
mutant myocilin accumulates in the ER.
Next, using our cell model, we wanted to determine the effect, if any, the clientchaperone relationship had on intracellular or secreted levels of myocilin. To do this, we
performed a siRNA screen on known ER-associated chaperones (Fig 1.2E). We
observed that in cells overexpressing WT myocilin, chaperone knockdown had no effect
on intracellular levels (Fig 1.2C) or secreted levels (Fig 1.2D) of myocilin. However, in
cells overexpressing the I477N mutant form of myocilin, Grp94 knockdown led to a
significant reduction in intracellular levels of myocilin (Fig 1.2A), while have no effect on
secreted levels (Fig 1.2B). This led us to the conclusion that Grp94 plays a significant
role in mutant myocilin accumulation. To further confirm this observation, we performed
immunofluorescent staining on cells overexpressing I477N mutant myocilin and
transfected with either control or Grp94 siRNA. Myocilin staining showed a 63%
reduction in intracellular mutant myocilin levels following Grp94 knockdown (Fig 1.2F).
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This result, in concert with the previous siRNA screen results, further validates Grp94 as
a major component in intracellular mutant myocilin accumulation, providing a
specialized target for further research.
Next, we wanted to further determine the client-chaperone relationship Grp94
and myocilin share. For this, we first performed a cycloheximide chase experiment on
cells overexpressing I477N mutant myocilin, in the presence or absence of Grp94, to
determine myocilin half-life under the described conditions. We observed, in the
presence of Grp94, mutant myocilin had a half-life of approximately 7.6 hours, whereas
in the absence of Grp94, mutant myocilin had a half-life of 2.9 hours (Fig 1.3A). This
showed the presence of Grp94 preserved mutant myocilin, leading to increased protein
deposition. Furthermore, we looked at insoluble protein accumulation by performing
western blots on cells overexpressing I477N mutant myocilin with Grp94 either
overexpressed with cDNA or knocked down with siRNA. We observed when Grp94 was
knocked down, there was a reduction of both soluble and insoluble forms of myocilin,
whereas cells overexpressing Grp94 had elevated insoluble and soluble intracellular
protein (Fig 1.3B&C). This further validated our conclusion that Grp94 is preserving
mutant myocilin intracellularly, while also showing that Grp94 is promoting insoluble
protein aggregation.
Finally, we wanted to determine Grp94 association with myocilin. For this, we
performed western blots on myocilin co-IP cell lysates overexpressing WT or I477N
mutant myocilin and probing for Grp94. We observed that Grp94 only associated with
cells overexpressing mutant I477N myocilin, while cells overexpressing WT myocilin
showed no Grp94 association whatsoever (Fig 1.4). These data proved that Grp94 only
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associates with the mutant form of myocilin, while not associating with or effecting WT
myocilin. Taken together, these data show a strong association between the ERassociate chaperone Grp94 and mutant forms of myocilin. The presence of Grp94 leads
to mutant myocilin sequestration within the ER, leading to protein accumulation and
aggregation. However, following Grp94 knockdown, mutant myocilin is able to be
degraded, albeit through an unknown mechanism.

1.4 Grp94 inhibition of interaction with mutant myocilin leads to intracellular
clearance via an autophagic mechanism.
After proving that Grp94 affects intracellular levels of mutant myocilin, and
knockdown of Grp94 leads to mutant myocilin clearance, we wanted to determine the
specific mechanism of mutant myocilin clearance following Grp94 knockdown.
Traditionally, terminally misfolded proteins in the ER are degraded through an ubiquitindependent proteasomal degradation pathway, known as ER-associated degradation
(ERAD) [25, 26]. Therefore, we hypothesized that mutant myocilin would be degraded
by ERAD following Grp94 knockdown. To test this hypothesis, we first looked at protein
ubiquitination in myocilin co-IP lysates of cells overexpressing WT, P370L, or I477N
mutant myocilin. We observed ubiquitin association with mutant forms of myocilin only
(Fig 1.5A). This further validated our hypothesis that accumulated mutant myocilin in the
ER is being targeted for ERAD. To definitively evaluate ERAD involvement we looked at
the effects of proteasomal inhibition on mutant myocilin clearance. We treated cells
overexpressing I477N mutant myocilin with epoxomicin, an inhibitor of proteasomal
degradation, and transfected the cells with either control or Grp94 siRNA. If ERAD was
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responsible for mutant myocilin degradation, we would expect epoxomicin treatment to
inhibit intracellular protein clearance. However, we observed significant reductions in
intracellular mutant myocilin protein levels following Grp94 knockdown and proteasomal
inhibition (Fig 1.5B). This led us to believe that mutant myocilin is in fact being degraded
through an alternative autophagic mechanism. To test the involvement of autophagy in
mutant myocilin degradation following Grp94 knockdown, we performed western blot
analysis on lysates from cells overexpressing I477N mutant myocilin, transfected with
Grp94 siRNA in addition to either Beclin1 or Lamp2 siRNA. Beclin1 and Lamp2 are
main components of the autophagic mechanism [27, 28], therefore, if autophagy was
responsible for mutant myocilin degradation following Grp94 knockdown, we would
expect the knockdown of these autophagic components to inhibit myocilin clearance.
Interestingly, knockdown of both Beclin1 (Fig 1.5C) and Lamp2 (Fig 1.5D) directly
inhibited mutant myocilin clearance following Grp94 knockdown. This led up to the
conclusion that following Grp94 knockdown, mutant myocilin is degraded through the
robust autophagic mechanism.
Finally, after showing the effects Grp94 gene knockdown had on mutant myocilin
intracellular accumulation, we wanted to determine if pharmacological inhibition of
Grp94 interaction with mutant myocilin would produce similar results. To do this, we
performed two dose response curves using known pan-HSP90 inhibitors, 17-AAG and
Celastrol, on cells overexpressing I477N mutant myocilin. We observed that these
inhibitors produced a dose dependent reduction in intracellular levels of mutant myocilin
(Fig 1.6A&B). Additionally, treatment with a steady concentration of 17-AAG provided a
time-dependent reduction of intracellular mutant myocilin (Fig 1.6C). Interestingly,

8

varying concentrations of 17-AAG had no effect on WT myocilin secretion (Fig 1.6D).
Finally, in collaboration with Dr. Brian Blagg at Kansas University, we received a Grp94
specific inhibitor, and tested its ability to reduce intracellular mutant myocilin in a
concentration dependent manner. We observed, similar to the pan-HSP90 inhibitors,
that the specific Grp94 inhibitor reduced intracellular mutant myocilin dose dependently
(Fig 1.6E). Taken together, these data revealed that specific pharmacological inhibition
of Grp94 interaction with mutant myocilin was sufficient to produce intracellular
degradation, providing a scaffold for further research and drug development.

1.5 Conclusions
Grp94 recognition and association with mutant myocilin produces intracellular
protein accumulation. Targeting Grp94 interaction with mutant myocilin has proven to be
viable method of reducing accumulated intracellular pathological myocilin. However, as
we are the first to discover this interaction, many unknowns remain about the complex
Grp94-mutant myocilin interaction as it relates to cell biology and POAG pathology.
Additionally, as Grp94 is a ubiquitous molecular chaperone, adverse effects of global
Grp94 inhibition remain unclear. Our initial specific Grp94 inhibitor proved potent at
reducing intracellular mutant myocilin in a dose dependent manner, however, off-target
effects remain unknown. Determining the chaperone-client relationship between Grp94
and other client proteins will help to perpetuate the production of more specific
pharmacological inhibitors, while also determining whether tissue-specific delivery
systems would be necessary. While no current research focuses on the Grp94-myocilin
interaction as it relates to POAG, Grp94 has been previously studied in terms of various
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cancer phenotypes. With a relatively short client list, Grp94 has promise as a valid
therapeutic target for the treatment of myocilin-associated POAG. More studies on this
chaperone-client relationship, as well as the development of more potent/ less toxic
inhibitors, transitioning to physiologically relevant POAG cell models, effects on multiple
mutant myocilin subtypes, and success in in vivo animal models will reveal the validity
of Grp94 as a target for myocilin-associated POAG treatment.
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Figure 1.1 Validation of inducible cell model. (A) Dot blot and Western blot analysis
of tetracycline-inducible HEK cells (iHEK) stably overexpressing either WT or I477N
mutant myocilin. (B) Co-localization immunofluorescent images of iHEK cells
overexpressing I477N mutant myocilin.
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Figure 1.2 siRNA-mediated knockdown of Grp94 regulates levels of I477N, but not
wild type, myocilin. (A) Western blot analysis of siRNA mediated knockdown of known
ER-associated molecular chaperones in iHEK cells overexpressing I477N mutant
myocilin. (B) Dot blot analysis of siRNA mediated knockdown of known ER-associated
molecular chaperones in iHEK cells overexpressing I477N mutant myocilin. (C) Western
blot analysis of siRNA mediated knockdown of known ER-associated molecular
chaperones in iHEK cells overexpressing WT myocilin. (D) Dot blot analysis of siRNA
mediated knockdown of known ER-associated molecular chaperones in iHEK cells
overexpressing WT myocilin. (E) Western blot analysis to prove proper gene
knockdown of previously mentioned chaperone siRNAs. (F) Immunofluorescent images
of iHEK cells expressing I477N mutant myocilin transfected with either control or Grp94
siRNA.
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Figure 1.3 Grp94 preserves mutant myocilin. (A) Western blot analysis of
cycloheximide chase experiment to test half-life of I477N mutant myocilin protein
following transfection with either control or Grp94 siRNA. (B) Western blot analysis of
soluble and insoluble myocilin species following transfection of control or Grp94 siRNA.
(C) Western blot analysis of soluble and insoluble myocilin species following
transfection of empty vector or Grp94 cDNA.
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Figure 1.4 Association of Grp94 with mutant but not wild type myocilin. Western
blot and dot blot analysis of myocilin co-IP cell lysates and media observing Grp94
association with WT or I477N mutant myocilin.
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Figure 1.5 Grp94 triages mutant myocilin through ERAD, enabling autophagic
degradation following Grp94 knockdown. (A) Myocilin co-IP of cell lysates looking at
ubiquitin association to various forms of myocilin. (B) Western blot analysis of iHEK
I477N cell lysates treated with increasing concentration of epoxomicin to inhibit
proteasomal degradation. Cells are transfected with either control or Grp94 siRNA and
probed for ubiquitin. (C) Western blot analysis of iHEK I477N cells co-transfected with
Grp94 siRNA and Beclin siRNA to inhibit autophagic degradation. (D) Western blot
analysis of iHEK I477N cells co-transfected with Grp94 siRNA and Lamp2 siRNA to
inhibit autophagic degradation.
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Figure 1.6 Inhibition of the HSP90 chaperone complex reduces levels of the
disease-causing I477N myocilin. (A) Dose dependent reduction of I477N mutant
myocilin following treatment with the pan-Hsp90 inhibitor, 17AAG. (B) Dose dependent
reduction of I477N mutant myocilin following treatment with the pan-Hsp90 inhibitor,
Celastrol. (C) Time dependent reduction of I477N mutant myocilin following single
concentration treatment (7.5uM) with 17AAG. (D) Dot blot analysis showing no change
in WT myocilin secretion following increasing dosages of 17AAG. (E) Dose dependent
reduction of I477N mutant myocilin following treatment with a novel specific Grp94
inhibitor.
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Chapter Two1:
Exploiting the interaction between Grp94 and aggregated myocilin to treat
glaucoma

2.1 Abstract:
Gain-of-function mutations in the olfactomedin domain of the MYOC gene facilitate the
toxic accumulation of amyloid-containing myocilin aggregates, hastening the onset of the
prevalent ocular disorder primary open-angle glaucoma. Aggregation of wild-type
myocilin has been reported in other glaucoma subtypes, suggesting broader relevance of
misfolded myocilin across the disease spectrum, but the absence of myocilin does not
cause disease. Thus, strategies aimed at eliminating myocilin could be therapeutically
relevant for glaucoma. Here, a novel and selective Grp94 inhibitor reduced the levels of
several mutant myocilin proteins as well as wild type myocilin when forced to misfold in
cells. This inhibitor rescued mutant myocilin toxicity in primary human trabecular
meshwork cells. Mechanistically, in vitro kinetics studies demonstrate that Grp94
recognizes on-pathway aggregates of the myocilin olfactomedin domain (myoc-OLF),
accelerates rates of aggregation, and co-precipitates with myoc-OLF. These results
indicate that aberrant myocilin quaternary structure drives Grp94 recognition, rather than

1

This work was previously published (Stothert AR et al, 2014) and is used with the permission of
the publisher
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peptide motifs exposed by unfolded protein. Inhibition of Grp94 ameliorates the effects of
Grp94-accelerated myoc-OLF aggregation, and Grp94 remains in solution. In cells, when
wild type myocilin is driven to misfold and aggregate, it becomes a client of Grp94 and
sensitive to Grp94 inhibition. Taken together, the interaction of Grp94 with myocilin
aggregates can be manipulated by cellular environment and genetics; this process can
be exploited with Grp94 inhibitors to promote the clearance of toxic forms of myocilin.

2.2 Introduction:
Primary open-angle glaucoma (POAG) is a degenerative eye disease
characterized by retinal ganglion cell loss and optic nerve head damage. This is often
preceded by increased intraocular pressure (IOP) due to impaired aqueous humor outflow
through the anterior anatomical segment called the trabecular meshwork (TM), leading to
irreversible vision loss [16, 29-31]. Mutations in the MYOC gene, which encodes the
myocilin protein, cause ~5% of hereditary POAG in populations throughout the world,
including approximately 100,000 people in the US [32, 33]. As a result, the pathogenic
mechanisms of mutant myocilin and its corresponding native biological function(s) have
been subjects of intensive investigation over the past decade [22, 34-36]. Myocilin,
composed of an N-terminal coiled-coil and 31 kDa C-terminal olfactomedin domain
(myoc-OLF), is generally believed to be a secreted protein [37]. The majority of the nonsynonymous MYOC gene lesions known to cause POAG are found within myoc-OLF [2,
38], leading to intracellular sequestration and aggregation [5, 8, 9, 14]. These
observations suggest a functional link between this domain and pathogenicity. The vast
majority of work in the field indicates that mutations in myocilin do in fact cause a toxic
gain-of-function for the protein [11, 39].
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Our team has recently provided a molecular basis for this toxicity: mutations in the
OLF domain of myocilin promote the toxic aggregation of the myocilin protein into amyloid
aggregates [38, 40]. This non-native structure is known to be nearly impossible to
disaggregate, likely explaining why, unlike other proteins, mutant myocilin cannot be
efficiently cleared by endoplasmic reticulum-associated degradation (ERAD) and instead
accumulates in the ER, leading to activation of ER stress pathways and TM cell death.
Indeed, we recently showed that knocking down or inhibiting the ER chaperone Grp94
facilitates the degradation of mutant myocilin in cells via autophagy. Grp94 preserves
mutant myocilin in the ER by attempting to force it through the ERAD pathway that
involves the valosin containing protein (VCP/p97) and the proteasome.
Here, we have identified a potent and selective Grp94 inhibitor that lowers the
levels of several mutant myocilin species. Grp94 inhibition reduces the toxicity of mutant
myocilin in human primary TM cells. The mechanism for Grp94 association with myocilin
is through its recognition of myocilin aggregates, not the folded mutant protein as
originally hypothesized. Based on this observation, we show that even wild type (WT)
myocilin, if misfolded and aggregated, can become a Grp94 client, and therefore can be
successfully degraded by inhibiting Grp94. Since ocular hypertension in glaucoma is
thought to be a result of the overexpression of WT myocilin [41, 42], Grp94 inhibition could
be more broadly applicable to glaucoma treatment than just for individuals with inherited
POAG.

19

2.3 Materials and Methods:
2.3.1 Cell Culture
HEK 293T cells were grown and maintained in Dulbecco’s modified Eagle’s
Medium supplemented with 10% FBS (Invitrogen), penicillin (100 units/mL), streptomycin
(100 µg/mL) and 1% GlutaMAX (Invitrogen) at 37 °C under 5% CO 2 .
Stably-transfected iHEK cells expressing myocilin were grown and maintained in
Dulbecco’s Modified Eagle’s Medium supplemented with 10% FBS (Invitrogen), penicillin
(100 units/mL), streptomycin (100 µg/mL) and 1% GlutaMAX (Invitrogen) at 37 °C under
5% CO 2 . For cell selection, the cells were supplemented with hygromycin B (200 µg/mL)
(InvivoGen) and G418 (100 µg/mL) (Gibco). To induce myocilin expression in these cells,
they were treated with 5 µg/uL tetracycline 24 h prior to transfection, or 48 h prior to
treatment.
Human trabecular meshwork cells (ScienCell) were plated on poly-L-Lysine coated
plates at a ratio of 1:10 poly-l-lysine to ddH 2 O. Cells were kept and maintained in
Fibroblast Medium (Sciencell) supplemented with 2% fetal bovine serum (ScienCell cat.
0010),

1%

fibroblast

growth

supplement

(ScienCell

cat.

2352),

and

1%

penicillin/streptomycin solution (ScienCell cat. 0503). HTM cells were maintained at 37
°C under 5% CO 2 .

2.3.2 cDNA and siRNA Transfection
All myocilin cDNA constructs were a generous gift from Dr. Vincent Raymond
(Laval University Hospital (CHUL) Research Hospital). Grp94 (SI02663738) and control
(1027281) siRNA was purchased from Qiagen (Valencia, CA) [43].
20

Plasmid transfections were carried out in serum-free opti-mem (Invitrogen)
medium. cDNA was mixed with Lipofectamine 2000 (Invitrogen) transfection reagent at a
ratio of 1 µg cDNA: 2.5 µL Lipofectamine 2000. cDNA was left on the cells for 48 h before
harvest. siRNA transfections were carried out in serum-free opti-mem (Invitrogen)
medium. siRNA was mixed with siLentFect (BioRad) lipid reagent for RNAi transfection.
Next, 40 nM of siRNA was added to cells, so that the siRNA to siLentFect ratio was 1 µL
siRNA to 2 µL siLentFect. siRNA was kept on the cells for 24 h prior to cDNA transfection
or drug treatment.

2.3.3 Antibodies
Myocilin monoclonal antibody was purchased from R&D Systems (Minneapolis,
MN (MAB3446)). Grp94 (2104S), Grp78 (3177S), Hsp70 (4873S), Hsp27 (2402S), and
DYKDDDK (Flag) (8146S) monoclonal antibodies were purchased from Cell Signaling
Technologies.

Glyceraldehyde-3-phosphate

dehydrogenase

(Gapdh)

antibody

(H86504M) was purchased from Meridian Life Science (Saco, ME). Actin antibody was
purchased from Sigma (A5316). Secondary antibodies were all HRP-linked and
purchased from Southern Biotechnolofies (Birmingham, AL). All antibodies were added
to blots in a 1:1000 dilution in 7% milk.

2.3.4 Pharmacological Treatment
Grp94 inhibitors were solubilized in DMSO (Sigma), and added to cells at varying
concentrations. All drug treatments were carried out for 24 h prior to cell harvest, and
DMSO never exceeded 1% of total volume of cell medium.
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2.3.5 Cell Harvest
For all cell harvesting, culture media was aspirated and cells were washed 2x in
ice cold phosphate-buffered solution (pH 7.4) (PBS). Mammalian Protein Extraction
Reagent (M-PER) buffer (Pierce) containing protease inhibitor mixture (Calbiochem), 100
mM phenylmethylsulfonyl fluoride (PMSF), and phosphatase inhibitor II and III mixtures
(Sigma) were added to the cells at a 1:100 dilution and cells were scraped. Cells in lysis
buffer were collected and incubated on ice for 10 min to allow lysis to occur. Cell lysates
were spun down at 16,000 x g to remove nuclear supernatant, and a bicinchoninic acid
assay (BCA) reaction was carried out to determine protein concentration.

2.3.6 Western Blotting and Co-Immunoprecipitation
Western blotting and Co-Immunoprecipitation were performed as previously
described [22]. Cell lysates were prepared with 2x Laemmli sample buffer (Bio-Rad) and
denatured by boiling for 5 min at 100 °C. Prepared lysates were then loaded onto a 10well 10% Tris-glycine gel (Invitrogen) or 18-well, 10% criterion gel (Bio-Rad). After
running, gels were transferred onto PVDF membranes (Millipore) and blocked for 1 h at
room temperature with 7% milk.
Co-Imunoprecipitation cell harvest was achieved in M-PER buffer supplemented
with protease inhibitor mixture, PMSF, and phosphatase inhibitor II and III mixtures. A
BCA reaction was performed to determine protein concentration, and the lysates were
incubated with myocilin antibody by rocking for 4 h to overnight at 4 °C. Next, 50 µL of
Protein G Dynabeads® (Novex by Life Technologies) were added to the samples and
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incubated by rocking overnight at 4 °C. Samples were washed with ice-cold PBS and
loaded onto gels for Western blot analysis.

2.3.7 Triton Solubility
HEK 293T cells were transfected with either Grp94 siRNA or Control siRNA 24 h
prior to mutant myocilin transfection. After a 48-h mutant myocilin transfection, cells were
washed twice with ice-cold PBS and lysed in buffer containing 100 mM Tris-HCl (pH 7.4),
3 mM EGTA, 5 mM MgCl 2 , 0.5% Triton X-100, protease inhibitor cocktail Calbiochem),
and 1 mM PMSF and incubated for 2 minutes on ice. Cells were spun down in a tabletop
centrifuge at 16,000 x g for 10 min. Supernatant was removed and kept as the Triton
soluble fraction. The pellet was washed with ice-cold PBS, and then re-suspended in 2x
Laemmli sample buffer with 9 M urea. The pellet was sonicated and denatured. Soluble
fractions were prepared with 2x Laemmli sample buffer, denatured, and run on Western
blot for analysis.

2.3.8 Tetrazolium Assay (MTS)
Assay is performed using CellTiter 96® Aqueous Non-Radioactive Cell Proliferation
Assay (Promega) kit. Cells are plated in a 96-well plate, and transfection/drug treatment
is carried out as previously reported. Manufacturer’s protocol was followed to complete
assay. Assay is read at 490 nm on a standard plate reader. The tetrazolium in the MTS
solution will react with live cells to form formazan, which is detectable at 490 nm. The
more formazan detected, the more viable the cells.
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2.3.9 Lentiviral Production and Transduction
Lentiviral vectors were created by sub-cloning c-terminal RFP-tagged cDNA from
a mammalian expression vector to the pLEX lentiviral vector. Second generation lentiviral
production required both a packaging plasmid (pPax2) and an envelope plasmid (VSVG). Lentiviral vector, packaging plasmid, and envelope plasmid were transfected into HEK
293T cells using Lipofectamine 2000 transfection reagent (Invitrogen) in serum-free
media. Cells with transfection reagent were placed in a 37 °C incubator with 5% CO 2 for
4 h. After 4 h, viral supernatant was removed and fresh serum-free media was added to
the cells. After 48-72 h the media containing viral particles was collected. The viruscontaining media was then centrifuged to remove cell debris, and filtered with a .45 µM
syringe filter. Virus-containing media was aliquotted and frozen at -80 °C for long-term
storage.
For lentiviral transduction, virus-containing media was added to cells in a 1:1
dilution with complete media. Polybrene (Santa Cruz) was added to the lentiviral mixture
at 8 µg/mL. HTM cell transduction was achieved after 7 days.

2.3.10 Immunofluorescence and Imaging
HTM Cells were plated on poly-l-lysine coated coverslips, and transduced with
RFP-tagged lentivirus, treated as described above. Cells were then fixed in 4%
paraformaldehyde, permeabilized in 0.1% Triton X-100 in PBS, and glycine-fixed in 0.1%
glycine in PBS. DAPI was used for a nuclear stain at 1:20,000 dilutions in PBS and
incubated for 5-10 min. Coverslips were then glued to glass tissue slides using ProLong®
Gold Antifade Reagent (Invitrogen). Images of cells were taken using the Olympus
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FV1000 MPE Multiphoton Laser Scanning Microscope. Image analysis of intensity was
carried out using ImageJ64 software (NIH).

2.3.11 Synthesis
Synthesis performed by Dr. Brian Blagg’s group at Kansas University. 4-Br-BnIm
4-bromo-benzylamine (32 μL, 0.26 mmol) was added dropwise to a stirred solution of
readily available aldehyde [44] (125 mg, 0.26 mmol) in MeOH (2 mL) followed by addition
of ammonium bicarbonate (20 mg, 0.26 mmol) and dropwise addition of 40% w/v glyoxal
(29 μL, 0.26 mmol). The reaction was stirred at 25°C for 12 h. Upon consumption of the
starting aldehyde, as seen by thin-layer chromatography, tetrabutylammonium fluoride
(0.52 mL, 1.0 M solution in THF) was added and the reaction was allowed to stir for an
additional 30 minutes.

The reaction was then quenched with saturated ammonium

chloride (5 mL) and then extracted with EtOAc (10 mL x 3). The organic layers were
combined, dried over Na 2 SO 4 and concentrated under reduced pressure. The resulting
residue was subjected to flash chromatography (95:5 CH 2 Cl 2 /MeOH) to provide 4-BrBnIm as an off white solid (45 mg, 38% yield). 1H NMR (400 MHz, CDCl 3 /MeOD) 7.457.41 (m, 2 H), 7.00 (d 1.39, 1 H), 6.88 (d 8.37, 2 H), 6.82 (d 1.38, 1 H), 6.45 (s, 1 H), 5.00
(s, 2 H), 3.86 (s, 3 H), 3.50-3.44 (m, 2 H), 2.88-2.82 (m, 2 H).

13

C NMR (500 MHz,

CDCl 3 /MeOD) 171.9, 163.5, 159.3, 148.8, 142.6, 136.1, 133.5 (2 C), 129.6 (2 C), 127.6,
123.5, 121.4, 116.0, 107.3, 104.07, 54.0, 50.4, 32.1, 27.2 HRMS (ESI) calculated for
C 20 H 19 BrClN 2 O 4 (M + H)+ 465.0217, found 465.0237
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2.3.12 Computational Modeling Based on Co-Crystal Structure
Molecular docking studies, performed by Dr. Blagg’s group were done using
Surflex-Dock module in Sybyl v8.0 from Tripos International (St. Louis, Mo). Co-crystal
structures of radamide bound to Grp94 and yeast Hsp82 were used for docking the
designed molecules [45]. Visual interpretation and rendering of the images were carried
out using the PyMOL Molecular Graphics System v1.5.0.4. from Schrödinger, LLC.

2.3.13 Fluorescence Polarization Assays
Flourescent polarization assays were performed by Dr. Blagg’s group. Increasing
concentrations of compound were incubated in 96-well plate (black well, black bottom)
format with recombinant cGrp94 (Enzo Life Sciences, 10 nM) and FITC-labeled
geldanamycin (Enzo Life Sciences, 6 nM) in assay buffer (20 mM HEPES pH 7.3, 50 mM
KCl, 5 mM MgCl 2 , 2 mM DTT, and 20 mM Na 2 MoO 4 , 0.01% NP-40, and 0.1 mg/mL BGG)
at a final volume of 100 μL per well. Plates were incubated for 24 h at 4 °C. Fluorescence
polarization values were measured using excitation and emission filters of 485- and 528nm, respectively. Polarization values were then normalized to DMSO (100% tracer
bound) and apparent K d values determined using GraphPad Prism software.

2.3.14 Quantification and Statistical Analysis
Quantification of Western blots was carried out using ImageJ64 software. Graphs
are plotted based on Intensity Density/Area values. Statistical analysis was performed as
indicated in the figure legends.
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2.4 Results:
2.4.1 Intracellular mutant myocilin levels and toxicity are reduced following Grp94
knockdown using siRNA.
We previously showed that Grp94 could regulate the levels of I477N-mutant
myocilin, but we sought to determine if modulating Grp94 levels could be generalized to
other disease-associated variants. HEK cells were transfected with myocilin harboring
I477N, Y437H, P370L, W286R or N480K substitutions and the effects of Grp94 overexpression (Fig. 2.1A) or siRNA knockdown (Fig. 2.1B) on their intracellular levels were
evaluated by Western blot. Over-expression of Grp94 preserved mutant myocilin in cells.
Conversely, Grp94 knockdown dramatically reduced the levels of each mutant myocilin
species. Optimal Grp94 knockdown of >60% was achieved with one of 3 siRNAs tested.
We then fractionated lysates from cells transfected with each myocilin mutant and either
control or Grp94 siRNA to determine the impact of Grp94 suppression on mutant myocilin
solubility, as previously described [14, 43]. Briefly, cells were lysed in a buffer containing
0.5% Triton, centrifuged at 16,000 x g for 10 minutes and supernatant was recovered for
the “soluble” fraction. The pellet from the spin was re-suspended in loading buffer and 9
M urea to produce the “insoluble” fraction. Grp94 knockdown reduced both soluble and
insoluble myocilin species, suggesting, as expected, that Grp94 suppression was
facilitating myocilin clearance, not forcing it into an insoluble state (Fig. 2.1C&D).
Quantification was achieved from 4 independent experiments, including those shown in
figures 2.1B and C. These findings further imply that Grp94 modulation is broadly
applicable to POAG cases resulting from different myocilin mutations.
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2.4.2 Improvement of Grp94 inhibitor efficacy through structure-based design.
We previously determined that the Grp94 inhibitor, BnIm 01, could reduce mutant
myocilin levels [43]. Based on molecular modeling studies of the pan-Hsp90 inhibitor
radamide bound to Grp94, Dr. Blagg’s group proposed the imidazole ring as a bioisosteric
replacement for the cis-amide moiety (Figs. 2.2A&B). Consistent with computational
predictions, the first compound synthesized, BnIm 01, exhibited ~100:1 selectivity for
Grp94 versus cytoplasmic Hsp90α/β, as determined by inhibition of Grp94-mediated Tolllike receptor protein presentation at the cell surface versus Western blot analyses of
Hsp90-dependent proteins found in the cytoplasm [44]. On the basis of our computational
model, Dr. Blagg’s group speculated that creating a molecule with increased
hydrophobicity at the C4-position of the N-benzyl group would improve drug interaction
with Grp94 and further prevent its interaction with Hsp90 proteins, thereby enhancing
selectivity [45].
To test this hypothesis, Dr. Blagg’s group synthesized 4-Br-BnIm (Fig. 2.2A);
modeling predicts this molecule fits more tightly into the hydrophobic pocket of Grp94
than the parent BnIm 01 (Fig. 2.2C). While in vitro fluorescence polarization binding
assays indicate its potency against Grp94 is only slightly increased (1.5 µM with the BnIm
01 compound compared to 1 µM with the 4-Br-BnIm compound) (Fig. 2.2D), 4-Br-BnIm
had an approximately 10-fold better effect on I477N mutant myocilin in HEK cells stably
over-expressing tetracycline-regulatable FLAG-tagged myocilin (iHEK) compared to
BnIm 01 (Fig. 2.3A&B). This improved potency in cells was likely due to better selectivity
for Grp94 over other Hsp90 proteins in cells [44]. We observed no changes in Grp78,
suggesting that ER stress was not activated by either inhibitor [46], nor did we observe
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an increase in heat shock proteins 27 or 70, indicating that our compound was selectively
targeting Grp94 over the cytosolic Hsp90 isoforms [47]. We also did not see any change
in Grp94 expression levels, suggesting that the inhibitors are reversibly binding to Grp94.
In addition, similar to BnIm 01, 4-Br-BnIm did not cause degradation of other Hsp90dependent clients Akt and Ras (Fig. 2.3C)[44]. We then evaluated whether 4-Br-BnIm
showed improved potency over BnIm 01 against other mutant myocilin species. Indeed,
4-Br-BnIm had greater efficacy against total myocilin levels of each mutant species tested
compared to BnIm 01 (Fig. 2.3D).

2.4.3 Grp94 inhibition reduces mutant myocilin levels and toxicity in primary human TM
cells.
We next sought to evaluate the efficacy of the selective and potent 4-Br-BnIm in
primary human TM cells because mutant myocilin is not known to be toxic to cells other
than TM cells. Lentiviral vectors were generated to express RFP-tagged WT and Y437H
mutant myocilin, along with RFP only as a control. TM cells were transduced with each
viral vector for 7 days and subsequently treated with 30 µM BnIm 01, 4-Br-BnIm, or an
equivalent volume of DMSO (vehicle) for 24 hours. Cells were counterstained with DAPI
and imaged using confocal microscopy (Fig. 2.4A). Quantification of RFP density
revealed that BnIm 01 and 4-Br-BnIm significantly reduced Y437H mutant myocilin while
WT myocilin and the RFP-only vector were largely unaffected by Grp94 inhibition (Fig.
2.4B). As was the case with the HEK cell system, 4-Br-BnIm resulted in better clearance
of Y437H-mutant myocilin than did BnIm 01. We then evaluated whether Grp94 inhibition
could be cytoprotective in TM cells ectopically expressing mutant myocilin using an MTS

29

assay. Y437H, but not WT myocilin, significantly reduced TM cell viability (Fig. 2.4C).
Impressively, both BnIm 01 and 4-Br-BnIm rescued this toxicity (Fig. 2.4C).

2.4.4 Post-translational modifications render wildtype myocilin a client of Grp94 via
misfolding.
In vitro studies have described several ways in which WT myocilin can aggregate
in the absence of a mutation, raising the possibility that misfolding of WT myocilin could
be occurring in sporadic cases of POAG, for example by induction of misfolding in relation
to post-translational modifications. Impaired glycosylation can prevent protein secretion,
but it is also known to cause protein misfolding. For myocilin, we predict this misfolding
could lead to production of early aggregates recognized by Grp94. Therefore, we tested
the effects of tunicamycin, a reagent known to inhibit N-linked glycosylation [48], on WT
myocilin and its subsequent ability to associate with Grp94 in cells. Indeed, transiently
over-expressed WT myocilin, which is not fully secreted [43], did become insoluble in cells
treated with tunicamycin (Fig. 2.5A), consistent with our cell-free data. Then, using the
iHEK cell model of WT myocilin over-expression, in which all WT myocilin is secreted, we
found that Grp94 associated with WT myocilin only in cells treated with tunicamycin,
further corroborating our in vitro observations (Fig. 2.5B). Conversely, WT myocilin did
not interact with Grp94 in these cells when treated with brefeldin A (BFA), a chemical that
blocks ER/Golgi transport and secretion without affecting myocilin folding, further
suggesting that the effects of tunicamycin on the myocilin/Grp94 interaction are due to
myocilin misfolding, and not impaired secretion (Fig. 2.5C). Then, using the same iHEK
cell model of WT myocilin over-expression, we found that tunicamycin blocked myocilin
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secretion, but this myocilin was sensitized to Grp94 inhibition (Fig. 2.5D&E), further
suggesting that misfolded myocilin becomes a Grp94 client.

2.5 Discussion:
Here, we have demonstrated the effectiveness of a second-generation Grp94selective inhibitor in clearing a number of POAG-relevant mutant myocilins in several cell
lines, including, importantly, primary human TM cells. Mechanistically, in vitro studies
indicate that Grp94 recognizes on-pathway aggregation intermediates, suggesting that
aberrant quaternary myocilin structure drives Grp94 client recognition rather than
exposed peptide motifs of individual misfolded or mutant proteins. When forced to misfold,
WT myocilin becomes an intracellular client of Grp94 that is then sensitized to Grp94
inhibition. Taken together, our work demonstrates that reducing mutant or aggregated
WT myocilin via inhibiting its interaction with Grp94 represents a viable therapeutic
strategy for myocilin-associated forms of glaucoma (Fig. 2.6).
Our findings also help explain the paradox of the failure of ERAD to triage
misfolded myocilin. Previously, we showed that mutant, but not wildtype, myocilin, was
recognized by Grp94, and that the degradation rate of mutant myocilin was increased
when Grp94 was depleted or inhibited [43]. This result was surprising because it
suggested that Grp94 was interfering with mutant myocilin clearance, rather than
facilitating its removal through the default ERAD pathway. Grp94 attempts to triage
mutant myocilin through ERAD but is unsuccessful, leading to its accumulation and missorting, which results in ER stress [16, 43]. Our current work shows that Grp94 cannot
triage mutant myocilin through ERAD because it recognizes an already-aggregated state
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of myocilin, and this association further accelerates aggregation into an amyloid structure
known to be resistant to resolubilization and refolding. This is not the first time that an
Hsp90 protein was shown to accelerate the aggregation of an amyloid-prone protein:
Hsp90α was previously shown to stimulate the aggregation of tau [49]. The evolutionary
reason for accelerated aggregation by a chaperone protein remains unclear, but one
possibility is that amyloid fibrils are typically less toxic than amorphous protein aggregates
[50, 51]. Thus, perhaps chaperones can stimulate amyloid structure to avoid the
production of amorphous structures that are more prone to non-specific interactions with
other proteins in the cell. However, in the case of myocilin amyloid, this innate function of
chaperones triggers an ER stress response, that culminates in TM cell death. Thus, in
this case, pharmacological inhibition of Grp94 reduces the interaction with aggregated
myocilin, and, as we showed previously, engages autophagic mechanisms that are better
equipped for handling protein aggregates while avoiding ER stress activation.
The BnIm scaffold holds considerable promise for selective Grp94 inhibition
without significant cellular side effects. New analogs that further exploit the hydrophobic
pocket occupied by the C4 position are currently under development. Efforts are also
currently underway to better understand the complex interaction between Grp94 and
myoc-OLF. Although the N-terminal ATP-binding domain of Grp94 contains the site of
4-Br-BnIm inhibition, other domains might provide the client protein recognition site;
inhibition may simply lock Grp94 in a configuration that occludes binding. Such
structural information could be valuable in developing new inhibitors remote from the Nterminal ATP binding site. Finally, the cellular mechanisms that lead to clearance of
myocilin after Grp94 inhibition are still not clear, but once defined, these too could be
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important targets for therapeutic development against myocilin and allow for a better
understanding of how aggregated proteins are removed from the ER.
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Figure 2.1 Consequences of Grp94 knockdown or over-expression on levels of
intracellular and aggregated mutant myocilin. A, HEK cells were co-transfected with
each indicated myocilin mutant and either Grp94 or Control 6TR cDNA. Western blot
analyses of cell lysates were performed 48 h after cDNA transfection. B, prior to
transfection with each myocilin mutant, cells were transfected with either Grp94 or
Control siRNA. Western blot analysis of cell lysates were performed 72 h following
siRNA transfection and 48 h after cDNA transfection. C, prior to transfection with each
myocilin mutant, cells were transfected with either Grp94 or Control siRNA. Triton
solubility fractions of cell lysates were analyzed by Western blot. D, Quantification of C
shows significant reductions in each myocilin mutant caused by Grp94 suppression by
siRNA as a percent of control siRNA following normalization to loading control. *
indicates p<0.05.
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Figure 2.2 Structure, modeling and activity of Grp94 inhibitors. All inhibitor
synthesis and binding performed by Dr. Brian Blagg’s Lab at Kansas University. A,
Structures of radamide, BnIm 01 and 4-Br-BnIm. B, BnIm 01 docked in a hydrophobic
pocket within the ATP binding site of Grp94 (based on radamide-bound structure, PDB:
2GFD). C, 4-Br-BnIm docked in Grp94 shows how the hydrophobic pocket can be
occupied with the hydrophobic substitution at C4 (indicated by arrow), which likely
improves specificity. D, Fluorescence polarization (FP) assay of recombinant Grp94
pre-incubated with FITC-labeled geldanamycin and then increasing concentrations of
each compound. Plates were incubated for 24h and FP measured at 485 ex and 528
em. FP values were normalized to DMSO (100% tracer bound).
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Figure 2.3 Effects of specific Grp94 inhibitors on levels of intracellular mutant
myocilin. A, Western blot analysis of HEK cells stably over-expressing tetracyclineregulatable FLAG-tagged I477N mutant myocilin lysates and treated with indicated
doses of BnIm 01 or 4-Br-BnIm for 24 h. Western blots were probed for myocilin levels,
as well as levels of other heat-shock proteins (Hsp27, Hsp70) and ER chaperones
(Grp78, Grp94). B, Quantification of A shows the half maximal effective concentration
(EC50) of BnIm 01 and 4-Br-BnIm for reducing mutant myocilin. C, Western blot
analysis of HEK cells stably over-expressing tetracycline-regulatable FLAG-tagged
I477N mutant myocilin lysates and treated with indicated doses of 4-Br-BnIm for 24 h.
Akt and Ras levels were unaffected by treatment. D, Western blot of lysates from HEK
cells transiently overexpressing five forms of mutant myocilin and treated with 30 µM
BnIm 01, 4-Br-BnIm, or equivalent volume of vehicle (Veh/DMSO) for 24 h.

36

Figure 2.4 Grp94 inhibitors reduce mutant myocilin levels and toxicity in HTM
cells. A, Immunofluorescence imaging of human trabecular meshwork (HTM) cells
transduced with RFP-tagged lentivirus expressing RFP control, RFP-tagged WT
myocilin, or RFP-tagged Y437H myocilin and treated with 30 µM BnIm 01, 4-Br-BnIm, or
equivalent volume of DMSO vehicle. Myocilin is shown in red and the nuclear marker
DAPI shown in blue (40x magnification). B, Quantification of immunofluorescence
images detecting RFP density ± standard deviation (n=3). Significance was measured
using the student’s t test; * indicates p<.05, ** indicates p<0.01. C, MTS assay of HTM
cells overexpressing WT or Y437H myocilin following treatment with 30 µM BnIm 01, 4Br-BnIm, or vehicle equivalent (DMSO) for 6 h. Cell viability is shown prior to treatment
(Pre-Tx) and following treatment (Post-Tx) ± standard deviation (n=3). Significance was
measured using the student’s t test; * indicates p<.05, ** indicates p<0.01.
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Figure 2.5 WT myocilin becomes a client of Grp94 when myocilin is misfolded. A,
Western blot analysis of Triton soluble/insoluble fractions from iHEK WT myocilin cell
lysates treated with 6µM tunicamycin for 24 h. B, Co-IP of myocilin and subsequent
Western blot analysis of iHEK WT myocilin cell lysates treated with 6µM concentration
of tunicamycin; Inputs indicates Western blot of lysates without co-IP. C, Co-IP of
myocilin and subsequent Western blot analysis of iHEK WT myocilin cell lysates treated
with 3µM concentration of Brefeldin A; Inputs indicates Western blot of lysates without
co-IP. D, Western blot analysis of iHEK WT myocilin cells treated with 6µM
concentration of tunicamycin followed by a dose response of BnIm 01, 4-Br-BnIm, or
equivalent volume of DMSO vehicle. E, Quantification of Western blot analysis on dose
response from D showing myocilin levels as a percent of vehicle following normalization
to loading control (Gapdh).
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Figure 2.6 Grp94 accelerates myocilin aggregation, a process that can be
prevented by Grp94 inhibition. Myocilin misfolding causes it to form small aggregates
that bind Grp94. Grp94 facilitates amyloid formation, preventing clearance of myocilin
and causing toxicity. Grp94 inhibitors prevent Grp94 from interacting with myocilin,
allowing a secondary autophagic pathway to facilitate clearance.
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Chapter Three:
Topical Ocular Administration of a Selective Grp94 Inhibitor Rescues Functional
Toxicities in a Mouse Model of Hereditary Primary Open Angle Glaucoma

3.1 Abstract
Over 70 mutations in exon 3 of the MYOC (myocilin) gene have been linked to
development of primary open-angle glaucoma (POAG). This genetic link has led many
to believe myocilin plays a vital role in both disease initiation and progression. Recent
work has demonstrated a direct interaction between mutant forms of myocilin and the
Hsp90 homolog, Grp94. This interaction preserved mutant myocilin within the
endoplasmic reticulum (ER) of trabecular meshwork (TM) cells, precipitating TM cell
dysfunction and downstream glaucomatous pathology. Here, we report the treatment of
myocilin-associated glaucomatous pathology in the Tg-MYOCY437H mouse model
through topical ocular administration of the specific Grp94 inhibitor, 4Br-BnIm. Following
chronic treatment with 4Br-BnIm, we observed a rescue of multiple pathologies
commonly associated with myocilin-induced glaucoma, including elevated intraocular
pressure, myocilin accumulation in the TM, reduced scotopic and photopic visual
responses, and retinal ganglion cell death. These results demonstrate the validity of
targeted Grp94 inhibition as a novel disease-modifying treatment for patients with
POAG.
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3.2 Introduction
Primary open-angle glaucoma (POAG) is a neurodegenerative optic neuropathy,
characterized by progressive irreversible vision loss [31] [52] [53] [54] [55]. Mutations in
the myocilin gene (MYOC) are the most common genetic link to clinical cases of POAG,
including the less common but more aggressive juvenile-onset open-angle glaucoma
(JOAG) [56]. There are over 70 documented MYOC mutations that have been linked
with glaucomatous pathology. Recent studies have shown that MYOC mutations lead to
a protein product that readily misfolds and accumulates within the endoplasmic
reticulum (ER) of trabecular meshwork (TM) cells [5, 8, 9, 14]. This accumulation
causes TM cell dysfunction, leading to reduced aqueous humor outflow, elevated
intraocular pressure (IOP), retinal ganglion cell (RGC) dysfunction, and loss of optic
nerve (ON) axons [57].
Clinically, treatment of POAG is best initiated when diagnosed early in the
disease progression. For patients with POAG, initial treatment options include
pharmaceuticals, such as alpha agonists, beta blockers, and prostaglandin analogs, to
reduce aqueous humor production at the ciliary body (CB) and promote alternative
outflow pathways [58] [59] [60] [61]. As the disease continually progresses, more
substantial surgical filtration therapies become necessary, such as sclerectomy or
trabeculectomy [62] [63] [64] [65]. While these therapies have proven to be effective at
reducing IOP and slowing progression of the disease, they are merely palliative in
nature and do not prevent the disease endpoint of irreversible blindness. To develop a
curative therapy, the underlying disease mechanisms must be targeted; however, this
has proven to be difficult, as a defined disease mechanism still remains a mystery.
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Our previous work has explored this disease mechanism and discovered a link
between mutant or misfolded forms of myocilin and the ER-associated Hsp90 homolog
glucose-regulated protein 94 (Grp94). We have shown that Grp94 recognition of
mutant/misfolded myocilin preserves the protein within the ER of TM cells, leading to
protein accumulation and aggregation, precipitating TM cell dysfunction [43,54]. When
the Grp94-misfolded myocilin interaction is inhibited, whether through gene knockdown
or pharmacological inhibition, the TM cell machinery regains the functional ability to
degrade and remove the misfolded protein, likely through a robust autophagic
mechanism [43, 54]. This has led us to hypothesize that Grp94 is directly responsible
for mutant myocilin pathology in POAG.
The current study initially investigated the myocilin interactome following
treatment with the Grp94 specific inhibitor 4Br-BnIm in cells to determine pathways
associated with myocilin triage following Grp94 inhibition. The efficacy of this compound
in vivo was then explored using topical ocular administration to evaluate glaucomatous
pathologies in these mice such as IOP, RGC function, and myocilin accumulation. Our
results indicate the validity of specific Grp94 inhibition as a potential first curative
therapeutic for patients suffering from myocilin-associated POAG.

3.3 Materials and Methods
3.3.1 Inhibitor synthesis
4Br-BnIm was synthesized and provided by Dr. Brian Blagg’s group at the
University of Kansas as previously described [54].
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3.3.2 Study Approval
All institutional guidelines for the care and use of animals were followed. All
animal handling and procedures were carried out in accordance with the University of
South Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance
with the Association for Assessment and Accreditation of Laboratory Animal Care
International (AALAC) regulations.

3.3.3 Animal Husbandry
The transgenic-Y437H mouse model (Tg-MYOCY437H) was a generous gift from
Val Sheffield at the University of Iowa. Characterization of the Tg-MYOCY437H mouse
was previously described [16,18]. Mice were housed and bred at the University of South
Florida Byrd Alzheimer’s Institute onto the C57BL/6 background. Mice heterozygous for
the Tg-MYOCY437H mutation were bred together to produce a 1:2:1 ratio of homozygous
transgenic: heterozygous transgenic: wild type littermates. Heterozygous littermates
were maintained for breeding, and homozygous transgenic and wild type littermates
were used for the study. Genotyping for the transgene was performed as previously
described by the Sheffield Lab [16,18].

3.3.4 Cell culture
Cell culture was performed as previously described [43]. Stably transfected iHEK
cells expressing I477N mutant myocilin were grown and maintained in Dulbecco’s
Modified Eagle’s Medium supplemented with 10% FBS (Invitrogen), penicillin (100
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units/ml), streptomycin (100 mg/ml) and 1% GlutaMAX (Invitrogen) at 37C under 5%
CO2. For cell selection, the cells were supplemented with hygromycin B (200 mg/ml)
(InvivoGen) and G418 (100 mg/ml) (Gibco). To induce myocilin expression in these
cells, they were treated with 5 mg/ml tetracycline 24 h prior to transfection, or 48 h prior
to pharmacological treatment.

3.3.5 Antibodies (cell culture)
Myocilin polyclonal antibody (1:1500) was a generous gift from W.D. Stamer at
Duke University [150]. Actin antibody (1:1000) was purchased from Sigma (A5316).
Secondary antibodies for western blots were all HRP-linked and purchased from
Southern Biotechnologies (Birmingham, AL). Primary and secondary antibodies were
added to western blots at a 1:1000 dilution in 7% milk.

3.3.6 Pharmacological treatment (cell)
Grp94 inhibitors were solubilized in DMSO (Sigma Aldrich), and added to cells at
the indicated concentrations. All drug treatments were carried out 24h prior to cell
harvest, and DMSO concentration never exceeded 1% of total volume of cell medium.

3.3.7 Cell Harvest
Cell harvest was performed as previously described [54]. Culture medium was
aspirated and cells were washed 2× in ice cold phosphate-buffered solution (pH 7.4)
(PBS). Mammalian Protein Extraction Reagent (M-PER) buffer (Pierce) containing
protease inhibitor mixture (Calbiochem), 100 mM phenylmethylsulfonyl fluoride (PMSF)
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and phosphatase inhibitor II and III mixtures (Sigma) were added to the cells at a 1:100
dilution and cells were scraped. Cells in lysis buffer were collected and incubated on ice
for 10 min to facilitate lysis. Cell lysates were spun down at 16000xg for 10min and a
bicinchoninic acid assay (BCA) reaction was carried out to determine protein
concentration for biochemical assessment of protein abundance.

3.3.8 Western blotting (cell)
Western blotting was performed as previously described [22]. After gel run was
complete, gels were transferred onto PVDF membrane (Millipore) at 100 volts for 1
hour. After transfer, blots were blocked with 7% milk in TBS for 1 hour at room
temperature before addition of primary antibody.

3.3.9 Inhibitor pharmacokinetics
PK studies performed by Dr. Brian Blagg’s group at Kansas University. Wild type
C57BL/6 mice were treated with topically administered 4Br-BnIm (~10 µL) at 100 µM
concentration. Eye drop remained on mouse eye for 1 minute before being irrigated off
with sterile PBS. Mice were then immediately euthanized, eyes enucleated, and flash
frozen. Isolated eye samples were diluted (0.1g/g in water) then homogenized by
vortexing in the presence of glass beads. Organics were extracted using EtOAc.
Following removal of EtOAc by evaporation, samples were diluted in MeCN/H 2 O (1:1) for
HPLC analysis. Concentrations of samples were determined after generating a standard
curve for 4Br-BnIm at known concentrations. HPLC Conditions: Agilent 1100 series
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quaternary pump, 1.0 mL/min, 50% MeCN/50% H 2 O, detection at 254nm. Column:
Agilent C-18 column, 4.6x150mm, 5µm. R t = 6.5 min.

3.3.10 Inhibitor application and study duration
4Br-BnIm dose concentration was determined by HPLC PK analysis observing
concentration of drug to cross the corneal epithelial barrier when applied topically.
Approximately 10% of the compound readily crossed the eye, therefore 300 µM stocks
were made up, which ensured a concentration of 30 µM would contact intraocular
tissues in the anterior chamber. Drugs were solubilized in DMSO and diluted in sterile
saline, so that the concentration of DMSO was 1%. Once a day, mice were restrained
and 1 drop (~10 µL) of drug was applied topically via eye drop. The drop was allowed to
sit on the eye for 1 minute before the mouse was returned to its cage. Mice were treated
1x/day for 14 weeks.

3.3.11 Intraocular Pressure (IOP) Measurements
Intraocular pressure (IOP) levels in the mouse eye were obtained using the Icare
TonoLab rebound tonometer (Icare, Finland). Bi-weekly, mice were briefly anesthetized
with Isoflourane at a 3-4% flow rate. Once induced, mice were quickly placed in a tube
restraint, and 6 IOP measurements were taken per eye. The 6 measurements were
then analyzed to determine standard deviation to determine consistency of the
measurements. If the standard deviation was within the parameters determined by the
machine, the mouse was removed from the restraints and returned to its cage. Animals
were anesthetized for no more than 2 minutes during the IOP measurement process.
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3.3.12 Electrophysiology
Electroretinograms (ERGs) were recorded from both eyes of each mouse posttreatment in a lightproof/soundproof booth. Animals were dark adapted for 24 hours
prior to data collection. Prior to ERG recordings, mice were anesthetized using a
Ketamine (100 mg/kg) and Acepromazine (1 mg/kg) mixture delivered via
intraperitoneal (IP) injection. Mouse health and vitals were monitored visually
throughout the experiment, with additional anesthesia given as needed. A custom ringshaped gold electrode was placed on the corneal limbus of each eye. Platinum needle
electrodes (Natus Neurology Inc., Warwick, RI) inserted in the temples and tail served
as references and ground readings, respectively. Recorded signals were differentially
amplified (2000x) and filtered (0.1-1000 Hz) by a multi-channel bio-amplifier (Xcell-3x4,
FHC Inc., Bowdoin, ME) and digitized at 1000 Hz. Light stimuli were produced by a
green LED (Vishay TLCTG5800, Newark Electronics, Palatine, IL) with an 8o emittance
angle positioned 1 cm perpendicularly to each cornea. The LEDs had a peak
wavelength of 520 nm and peak output of 2100 cd/m2 measured with a calibrated
photometer (UDT Instruments Inc., Baltimore, MD). Full-field scotopic ERGs (n35-p50)
were recorded for a series of 200 brief (10ms) flashes (1.32 log cd·s/m2) delivered to
both eyes simultaneously. LED light intensity was gradually increased to determine
lowest possible intensity to evoke an ERG response. After scotopic recording, mice
were exposed for 30 min to ambient room light (15 cd/m2) from an LED strip that lined
the booth ceiling. After light-adaption, full-field photopic ERGs (p50-n95) were recorded.
LED flash sequences were separated by a 3 second interval, to allow sufficient time for
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mice to fully recover from the previous LED flash, ensuring validity of ERG recordings.
Light-evoked signals were quantified in terms of scotopic (n35-p50)/photopic (p50-n95)
wave amplitude. Wave amplitudes were measured from the trough-to-peak (n35-p50) or
peak-to-trough (p50-n95). Statistical analysis was performed using SigmaPlot 13.0
software (San Jose, CA) and graphs were generated with GraphPad Prism 5.0
software.

3.3.13 Eye enucleation
Mice were euthanatized with a .2% Somnasol (50 mg/kg) in saline solution. Eyes
were gently removed from the skull preserving the morphology of the eye globe. Once
removed from the skull, eyes were either fixed in Davidson’s (1:3:2:3, glacial acetic acid:
95% ethanol, 10% neutral buffered formalin, distilled water) solution for histology, or
micro-dissected to remove the retinas.

3.3.14 Whole retinal mount
Post-enucleation, mouse eyes were micro-dissected to remove the intact retina.
Eyes were placed in an isotonic solution, and the cornea was removed using surgical
micro-scissors. The iris was gently pulled away from the lens, and the lens was
removed using tweezers. The remaining eye cup contained the retina and sclera.
Gently, the retina was peeled away from the sclera, producing a whole intact retina.
Retinas were placed in 10% neural buffered formalin for fixation for 48 hours and then
moved to a dPBS+ Sodium Azide solution for storage until tissue staining.
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3.3.15 Histological processing of mouse eye tissue
Enucleated mouse eyes were immediately fixed in Davidson’s Solution for 48
hours. Davidson’s solution was used to maintain good nuclear detail without formalin
pigmenting. After 48 hour fixation, eyes were switched to 10% neutral buffered formalin
for shipping. Fixed eyes were shipped to HistoWiz Inc. (Brooklyn, NY, USA) where
tissue was processed, paraffin embedded, sectioned, and mounted on slides. Sections
were cut longitudinally at a thickness of 10 microns. Slides were returned to our lab for
deparaffinization and tissue staining.

3.3.16 Tissue deparaffinization/rehydration
Modified from an existing Abcam protocol (www.abcam.com/protocols/ihcdeparaffinization-protocol). Slides were placed in a glass slide rack, and
deparaffinized/rehydrated using the following steps: 2x 3min wash in Xylenes, 1x 3min
wash in 1:1 Xylenes:100% ethanol, 2x 3min wash in 100% ethanol, 1x 3min wash in
95% ethanol, 1x 3min wash in 75% ethanol, 1x 3 min wash in 50% ethanol, keep in
ddH2O until antigen retrieval. After rehydration, at no point were the slides/tissue
allowed to dry out.

3.3.17 Antigen Retrieval
After deparaffinization, slides were submersed in a Sodium Citrate Buffer (10mM
Sodium Citrate, 0.05% Tween 20, ph 6.0) in a microwave safe plastic coplin jar. The
coplin jar was placed in a water bath, to maintain a constant temperature, and
microwaved at 2 minute increments, replacing water and sodium citrate butter after
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each heating cycle. This process was repeated three times, ensuring heat-induced
epitope retrieval.

3.3.18 Tissue staining
After deparaffinization and antigen retrieval, whole eye section slides were
fluorescently stained as previously described [67]. Briefly, following permeabilization,
tissue was incubated with myocilin (Santa Cruz (21243), Dallas, TX, 1:50) primary
antibody overnight. The following day, sections underwent PBS washing, and tissue
was incubated with Alexa Fluor 594 donkey anti-goat IgG (Invitrogen (11058), Grand
Island, NY; 1:500) secondary antibody for 2 hours.
For whole mount retinas, tissue sections were free-floating fluorescently stained
as previously described above. Briefly, following permeabilization, tissue was incubated
with γ-synuclein (Abcam (55424), Cambridge, UK, 1:1000) primary antibody overnight.
The following day, sections underwent PBS washing, and tissue was incubated with
Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen (11008), 1:1000) secondary antibody for
2 hours. Whole retinas were mounted and both whole eye and whole retina slides were
cover slipped using ProLong Gold Antifade Reagent (Invitrogen).

3.3.19 Tissue imaging, quantification, and analysis
Both myocilin stained whole eye sections and γ-synuclein stained whole retinas
were imaged using the Olympus FV1200 MPE Multiphoton Laser Scanning Microscope
using a 40x objective (scale bar = 40 µM). All fluorescent quantification was carried out
using ImageJ analysis software (National Institutes of Health). Myocilin was quantified in
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the TM of whole eye slices for fluorescence intensity. Gamma-synuclein was quantified
for the entire retina section for both fluorescence intensity, and positively stained cells.
To determine positively stained cells, a fluorescence threshold was determined. Particle
analysis was performed on areas between 0 and infinity pixels2 and a circularity of 0.001.00, which allowed for the analysis of all positive gamma-synuclein staining. For whole
eye sections, each mouse had 2 TMs analyzed. These values were then averaged to
determine average myocilin levels in each mice. For whole mount retinas, analysis was
taken of the retina as a whole, measuring total number of positive cells and intensity of
positively stained cells.

3.3.20 Quantification and Statistical Analysis
Statistical analysis of IOP, ERG, and fluorescent images was performed using
student’s t-test, comparing each individual treatment group. Values were considered
significant if p<0.05. Graphs were generated using GraphPad Prism 5.0 analysis
software.

3.4 Results
3.4.1 The selective Grp94 antagonist 4Br-BnIm triages mutant myocilin and possesses
trans-scleral permeability
We have previously shown that the specific Grp94 inhibitor, 4Br-BnIm, was
effective at clearing intracellular mutant myocilin, inhibiting in vitro myocilin protein
aggregation, and alleviating TM cell dysfunction [54]. To properly translate these results
to an in vivo mouse model for glaucoma, we set out to determine if 4Br-BnIm would be
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effective as an ocular treatment (Fig. 3.1A). First, to confirm intracellular mutant myocilin
reduction by 4Br-BnIm treatment, iHEK cells overexpressing I477N mutant myocilin
were treated with increasing concentrations of 4Br-BnIm, and intracellular myocilin
levels were evaluated by western blot (Fig. 3.1B). Densitometry quantification revealed
4Br-BnIm reduced intracellular mutant myocilin levels, with almost 50% reduction at a
30 µM concentration (Fig. 3.1C).
However, to definitively determine the effectiveness of this compound as a
topical ocular treatment, the pharmacokinetic (PK) efficiency of crossing the corneal
epithelial barrier when applied topically was tested. PK studies performed by Dr. Brian
Blagg’s Lab at Kansas University. One drop (~10 uL) of 4Br-BnIm was applied to the
eye and allowed to permeate for 1 minute. Mouse eyes were subsequently harvested,
homogenized and analyzed through high performance liquid chromatography (HPLC) to
determine the intraocular concentration of the compound. Quantification of these results
revealed 13.1±2.7% of 4Br-BnIm could effectively cross the corneal epithelial barrier.
These data demonstrated that 4Br-BnIm was a viable candidate for topical ocular
administration, as the bioavailability of current ophthalmic medications is considered
acceptable at a rate of approximately 5% [68].Therefore, we determined a dose of 300
uM, with approximately 10% of the compound effectively crossing the corneal epithelial
barrier, would ensure approximately a 30 µM concentration of 4Br-BnIm was reaching
intraocular tissues in the anterior chamber of the eye when applied topically.
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3.4.2 Intraocular pressure elevation in Tg-MYOCY437H mice is rescued by topical ocular
treatment with 4Br-BnIm
In our previous in vitro work, we showed that inhibition of Grp94 association with
misfolded or mutant myocilin was sufficient to induce intracellular protein clearance [43]
[54]. Therefore, we sought to determine if this could be translated to pathology reduction
in vivo in the Tg-MYOCY437H mouse model of glaucoma. Mice were aged to 4 months to
ensure the development of pathology, and then separated into 4 distinct treatment
groups: wild–type (WT) + vehicle (n=6), WT + 4Br-BnIm (n=6), transgenic (Tg) + vehicle
(n=12), and Tg + 4Br-BnIm (n=14). Animals received daily topical ocular treatment as
described in the methods. Bi-weekly, IOP measurements were recorded on each
individual eye (Fig. 3.2A). Baseline readings for the WT mice were measured at 13.83 ±
.55 and 13.5 ± .70 mm Hg for the vehicle and 4Br-BnIm groups, respectively. Baseline
readings for the Tg mice were measured at 19.17 ± .61 and 19.86 ± .43 mm Hg for the
vehicle and 4Br-BnIm treated groups, respectively. There was no significant difference
between transgenic treatment groups prior to treatment phase (p=.3721) (Fig. 3.3B).
Post-treatment IOP readings for WT mice were measured at 12.83 ± .28 and 13.17 ±
.28 mm Hg for the vehicle and 4Br-BnIm treated groups, respectively. Post-treatment
readings for Tg mice were measured at 17.5 ± .28 and 14.0 ± .34 mm Hg for the vehicle
and 4Br-BnIm treated groups, respectively. Tg mice treated with vehicle had
significantly higher IOP readings than Tg mice treated with 4Br-BnIm following the
treatment period (p=.0001)(Fig. 3.2B). These findings imply that topical ocular treatment
of 4Br-BnIm is sufficient to reduce elevated IOP levels in the Tg-MYOCY437H mouse
model of glaucoma.

53

3.4.3 Myocilin accumulation in the trabecular meshwork of Tg-MYOCY437H mice is
reduced following topical ocular treatment with 4Br-BnIm
As we have previously shown, 4Br-BnIm is effective at reducing intracellular
levels of mutant myocilin in in vitro primary TM cell models [54]. To determine if 4BrBnIm had the same effect in the Tg-MYOCY437H mouse model, we performed
immunohistological staining of myocilin in the TM (Fig. 3.3A). Quantification of
immunostaining for fluorescent intensity revealed no significant difference in myocilin
levels when comparing WT + vehicle (n=4) and WT + 4Br-BnIm (n=6) treatment groups
(p=.9588) (Fig. 3.3B). This allowed us to group all WT mice together for comparison
with Tg-MYOCY437H treatment groups. Tg-MYOCY437H + vehicle (n=14) mice had
significantly more myocilin accumulation in the TM compared to WT mice (p=.0002).
Importantly, Tg-MYOCY437H + 4Br-BnIm (n=10) mice showed no significant difference in
myocilin levels in the TM compared to WT mice (p=.5933) (Fig. 3.3C). Collectively,
these data indicate that topical ocular administration of 4Br-BnIm had a profound effect
on TM tissue in Tg-MYOCY437H mice, further validating 4Br-BnIm as a viable therapeutic
targeting pathology associated with POAG.

3.4.4 Scotopic and photopic vision is preserved in Tg-MYOCY437H mice following topical
ocular treatment with 4Br-BnIm
In order to determine retinal cell health, we evaluated the scotopic visual
response of Tg-MYOCY437H mice, using dark-adapted electroretinography (ERG). Mice
were dark adapted for 24 hours prior to ERG readings. Representative tracings of dark-
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adapted ERG show scotopic (n-35-p50) wave amplitudes (Fig. 3.4A). Quantification of
these dark-adapted ERG tracings showed no significant difference between WT
treatment groups n35-p50 wave amplitudes (p=.8255) (Fig. 3.4B). As previously
reported [18], Tg mice treated with vehicle had significantly reduced n35-p50 wave
amplitudes compared to WT mice (p=.0134). However, Tg mice treated with 4Br-BnIm
displayed no significant difference in n35-p50 wave amplitudes compared to WT mice
(p=.3652) (Fig. 3.4C), once again demonstrating the effectiveness of the compound.
To determine the photopic visual response of Tg-MYOCY437H mice, we performed
light-adapted ERG, exposing the mice to ambient room light for 30 minutes following
dark-adapted ERG recordings. Representative tracings of light-adapted ERG photopic
(p50-n95) wave amplitudes are depicted in Fig. 3.4D. Quantification of these lightadapted ERG tracings showed no significant difference between WT treatment groups
p50-n95 wave amplitudes (p=.6850) (Fig. 3.4E). Similar to the scotopic response, Tg
mice treated with vehicle displayed significantly reduced p50-n95 wave amplitudes
compared to WT mice (p=.0140). Again, Tg mice treated with 4Br-BnIm had no
significant difference in p50-n95 wave amplitudes compared to WT mice (p=.5310) (Fig.
3.5F). These data suggest that topical ocular administration of 4Br-BnIm can preserve
both scotopic and photopic visual responses, thus effectively preserving retinal neuronal
cell activation.
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3.4.5 Retinal ganglion cell viability is preserved in Tg-MYOCY437H mice following topical
ocular treatment with 4Br-BnIm
RGC viability was evaluated by whole-mount γ-synuclein staining of mouse
retinas comparing WT mice to each Tg treatment group. First, total RGC cell count was
determined using ImageJ software to quantify the number of positive cells (Fig. 3.5A).
Quantification showed a significant reduction (69%) in positively stained RGC cells in Tg
mice treated with vehicle as compared to WT mice (p=.0002). There was no significant
difference between Tg mice treated with 4Br-BnIm and WT mice (p=.7945) (Fig. 3.5B).
Next we looked at intensity of fluorescent γ-synuclein staining to determine overall
viability of healthy RGCs (Fig. 3.5C). Quantification showed a significant reduction in
fluorescent intensity (90%) in Tg mice treated with vehicle as compared to WT mice
(p=.0023). There was no significant difference in fluorescent intensity of γ-synuclein
staining in Tg mice treated with 4Br-BnIm compared to WT mice (p=.5846) (Fig. 3.5D).
These findings, taken together with the ERG data, suggest that topical ocular treatment
with 4Br-BnIm preserved retinal cell health and function in the Tg-MYOCY437H mouse
model, allowing normal signal transduction and conversion of light waves into visual
signals in the visual cortex of the brain.

3.5 Discussion
Here, we have further validated specific Grp94 inhibition as a viable therapy for
treating myocilin-associated POAG by restoring TM cell function and reducing
glaucomatous pathology in the Tg-MYOCY437H mouse model. Previously, we have
shown that specific Grp94 inhibition leads to a reduction in myocilin accumulation and
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cellular dysfunction in primary human TM cells [54]. Additionally, we have shown that in
vitro myocilin aggregation is significantly reduced following protein incubation with 4BrBnIm [54]. The current study demonstrated that these previous in vitro cell and protein
assay results translate to effective in vivo treatment of myocilin-associated POAG
pathologies. These findings underscore the potential therapeutic benefit of specific
Grp94 inhibition as a treatment for patients with myocilin-associated POAG and further
define a specific disease mechanism of POAG pathology. The results from the mass
spectrometry also elucidate the intracellular mechanisms of mutant myocilin
degradation, which will provide valuable insight into Grp94-mediated myocilin triage.
TM tissue is the main component of the conventional outflow pathways of
aqueous humor. Several studies have shown that accumulation of myocilin in the TM
precipitates TM cellular dysfunction [16, 18, 54, 77], leading to the pathologies
commonly associated with POAG, including increased IOP, RGC cell death, and
eventually irreversible blindness. Therefore, if effective, by reducing mutant myocilin
accumulation in the TM, normal TM cell function can be restored in the human eye,
preventing downstream POAG pathologies from being initiated. Here, we have shown
that topical ocular administration of 4Br-BnIm significantly reduced myocilin levels in the
TM. This suggests that specific Grp94 inhibition is a viable method for restoring normal
TM cell function in patients with POAG.
The functional pathologies associated with myocilin-induced POAG include
elevated IOP, diminished scotopic/photopic visual responses, and deterioration of RGC
health/function. Importantly, topical ocular administration of 4Br-BnIm led to a significant
reduction in each of these functional pathologies, demonstrating its broad therapeutic
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utility. The effectiveness and potency of specific Grp94 inhibition as a viable treatment
for POAG pathologies also highlights the vital role Grp94 plays in POAG disease
progression. Prior to our work, Grp94 was mainly studied for its pro-oncogenic
properties as it relates to cancer development [78-80]. Specifically, how elevated levels
of Grp94 are a molecular hallmark of tumor metastasis [81-83]. With Grp94’s clear
involvement in other degenerative diseases, it would be prudent to further explore nonprimary open-angle forms of glaucoma, including closed-angle and secondary
glaucoma, to determine what role, if any, Grp94 plays in their disease progression.
In conclusion, this study revealed the effectiveness and potency of specific
Grp94 inhibition as a viable treatment method for POAG. Autophagic degradation of
mutant myocilin following specific Grp94 inhibition leads to restoration of TM cell
function, reduced IOP, and preserved retinal cell function, ultimately restoring health
and function of the eye (Fig. 3.6). Grp94 inhibition holds considerable promise as a
potential disease-modifying treatment of POAG. New compounds that are more potent
at reducing intracellular myocilin at lower concentrations, while also readily crossing the
corneal epithelial barrier are currently under development. Efforts are also currently
underway to determine the most effective means of drug delivery into the eye, to target
TM cells while reducing off-target effects. Although topical ocular administration
provided significant reductions in pathologies associated with POAG, other means of
delivery, such as anterior chamber micro-injections, could prove to be more effective at
directly targeting the TM. Studies exploring potency, bioavailability, means of delivery,
and disease mechanism will be vital in progressing this research into human clinical
trials and developing an effective treatment for patients with POAG.
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Figure 3.1 4Br-BnIm reduces intracellular mutant myocilin. (A) Structure of specific
Grp94 inhibitor, 4Br-BnIm. (B) Tetracycline-inducible Hek cells (iHEK) overexpressing
the disease-associated I477N mutant myocilin were treated with increasing doses of
4Br-BnIm to determine a dose response. Western blot analysis of cell lysates were
performed 24 h after drug treatment. (C) Quantification of (B) shows effective reduction
of intracellular mutant myocilin when treated with 4Br-BnIm.
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Figure 3.2 Topical ocular 4Br-BnIm reduces intraocular pressure in TgMYOCY437H mice. (A) Intraocular pressure (IOP) levels as recorded by rebound
tonometry for four treatment groups (WT + vehicle (n=6), WT+Grp94 Inhibitor (n=6), Tg
+ vehicle (n=12), Tg+Grp94 Inhibitor (n=14)). Readings were recorded every two weeks
throughout the treatment period. Time=0 represents the IOP of animals prior to
treatment initiation. Treatment period began at age=4 months, and occurred 1x/day for
the duration of the study. (B) Quantification of (A) comparing average IOP levels of the
four treatment groups pre- and post- treatment cycle. Initially, there was no statistical
difference between Tg groups prior to treatment (p=.3721) (19.2 to 19.9 mmHg).
However, after the treatment period we observed a significant reduction in IOP for the
Tg+Grp94 Inhibitor group compared to Tg + vehicle group (p=<.0001) (14.0 to 17.5
mmHg), returning to levels consistent with both WT treatment groups (13mmHg).
Statistical analysis carried out using two-tailed t-test. *P<.05, **P<.001, ***P<.0001.
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Figure 3.3 Topical ocular 4Br-BnIm reduces intracellular myocilin accumulation in
the TM of Tg-MYOCY437H mice. (A) Representative images showing myocilin (Santa
Cruz (21243)) accumulation in the TM of WT and Tg-MYOCY437H mice topically
treated with vehicle or 4Br-BnIm by fluorescent immunostaining and multiphoton
microscopy. Trabecular meshwork (TM) and ciliary body (CB) are marked. (B)
Quantification of (A) showing fluorescent intensity translating to myocilin accumulation
levels comparing WT + vehicle (n=6) group to WT + 4Br-BnIm (n=4). There is no
significant difference between wildtype mice treatment groups (p=.9588). (C)
Quantification of (A) showing myocilin accumulation in both Tg mouse treatment groups
compared to WT mice. Tg-MYOCY437H + vehicle (n=14) have significantly more
myocilin accumulation compared to WT mice (p=.0002). Tg-MYOCY437H + 4Br-BnIm
(n=10) are not significantly different in myocilin accumulation compared to WT mice
(p=.5933). Scale bar, 40uM. Statistical analysis carried out using two-tailed t-test.
*P<.05, **P<.001, ***P<.0001.
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Figure 3.4 Topical ocular 4Br-BnIm restores scotopic and photopic vision in TgMYOCY437H mice. (A) Representative tracings of average scotopic (N35-P50) wave
amplitudes in dark-adapted mice. (B) Quantification of (A) comparing WT treatment
groups (WT + vehicle (n=4), WT + 4Br-BnIm (n=6)) N35-P50 wave amplitude.
Statistically, there was no difference between WT groups (p=.8255), allowing us to
group all WT mice together (n=10) (40.7 ± 2.7uV). (C) Quantification of (A) comparing
Tg treatment groups (Tg + vehicle (n=7), Tg+4Br-BnIm (n=8)) to WT group. Tg mice
treated with vehicle had significantly diminished (p=.0134) N35-P50 wave amplitude
compared to WT mice (28.8 ± 3.0uV to 40.7 ± 2.7uV). Tg mice treated with Grp94
inhibitor were not statistically different (p=.3652) from WT mice (36.5 ± 3.6uV to 40.7 ±
2.7uV). This shows a recovery in N35-P50 wave amplitude in Tg mice following Grp94
Inhibitor treatment. (D) Representative tracings of average photopic P50-N95 wave
amplitudes in light-adapted mice. (E) Quantification of (D) comparing WT treatment
groups (WT + vehicle (n=4), WT+4Br-BnIm (n=6)) P50-N95 wave amplitude.
Statistically, there was no difference (p=.6850) between WT groups, allowing us to
group all WT mice together (n=10) (45.0 ± 6.0uV). (F) Quantification of (D) comparing
Tg treatment groups (Tg + vehicle (n=10), Tg+4Br-BnIm (n=8)) to WT group. Tg mice
treated with vehicle had significantly diminished (p=.0140) P50-N95 wave amplitude
compared to WT mice (27.4 ± 2.4uV to 45.0 ± 6.0uV). Tg mice treated with Grp94
inhibitor were not statistically different (p=.5310) from WT mice (39.6 ± 5.6uV to 45.0 ±
6.0uV). This shows a recovery in P50-N95 wave amplitude in Tg mice following Grp94
Inhibitor treatment. Statistical analysis carried out using two-tailed t-test. *P<.05.
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Figure 3.5 Topical ocular 4Br-BnIm preserves RGC viability in Tg-MYOCY437H
mice. (A) Representative images showing gamma-synuclein (Abcam (55424)) positive
cells translating to viable retinal ganglion cells in whole mounted retinas. Positive cell
threshold was determined using ImageJ analysis software. (B) Quantification of (A)
comparing gamma-synuclein positive retinal ganglion cells in WT (n=3) to Tg mouse
treatment groups. Tg + vehicle (n=4) treated mice had significantly less gammasynuclein positive cells than WT mice (p=.0002). Tg + 4Br-BnIm (n=4) mice did not have
a significantly different amount of gamma-synuclein positive cells (p=.7945). (C)
Representative images showing gamma-synuclein staining intensity of retinal ganglion
cells in whole mounted retinas. (D) Quantification of (C) comparing gamma-synuclein
staining intensity in WT (n=3) to Tg mouse treatment groups. Tg + vehicle (n=4) treated
mice had significantly lower gamma-synuclein intensity than WT mice (p=.0023). Tg +
4Br-BnIm (n=4) mice did not have a significantly different intensity of gamma-synuclein
staining (p=.5846). Scale bar, 40uM. Statistical analysis carried out using two-tailed ttest. *P<.05, **P<.001, ***P<.0001.
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Figure 3.6 4Br-BnIm inhibits Grp94 association with mutant myocilin, reducing
pathologies associated with POAG. In a healthy eye, myocilin is produced in the ER
of TM cells. If there is a mutation in the myocilin genome, a protein product is produced
that readily accumulates and aggregates due to recognition by Grp94. If mutant myocilin
is allowed to aggregate within the ER of TM cells, cellular dysfunction occurs, leading to
POAG associated pathologies. Using the specific Grp94 inhibitor, 4Br-BnIm, Grp94
association with mutant myocilin is inhibited allowing for alternative degradation via
autophagy. Myocilin degradation restores TM cell function, leading to reduced IOP and
retinal cell preservation.
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Chapter Four1:
Targeting the ER-Autophagy System in the Trabecular Meshwork to Treat
Glaucoma
4.1 Abstract
A major drainage network involved in aqueous humor dynamics is the conventional
outflow pathway, which is gated by the trabecular meshwork (TM). The TM acts as a
molecular sieve, providing resistance to aqueous outflow, which is responsible for
regulating intraocular pressure (IOP). If the TM is damaged, aqueous outflow is
impaired, IOP increases and glaucoma can manifest. Mutations in the MYOC gene
cause hereditary primary open-angle glaucoma (POAG) by promoting the abnormal
amyloidosis of the myocilin protein in the endoplasmic reticulum (ER), leading to ER
stress-induced TM cell death. Myocilin accumulation is observed in approximately 7080% of all glaucoma cases suggesting that environmental or other genetic factors may
also promote myocilin toxicity. For example, simply preventing myocilin glycosylation is
sufficient to promote its abnormal accretion. These myocilin amyloids are unique as
there are no other known pathogenic proteins that accumulate within the ER of TM cells
and cause toxicity. Moreover, this pathogenic accumulation only kills TM cells, despite
expression of this protein in other cell types, suggesting that another modifier exclusive
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to the TM participates in the proteotoxicity of myocilin. ER autophagy (reticulophagy) is
one of the pathways essential for myocilin clearance that can be impacted dramatically
by aging and other environmental factors such as nutrition. This review will discuss the
link between myocilin and autophagy, evaluating the role of this degradation pathway in
glaucoma as well as its potential as a therapeutic target.

4.2 Introduction
Aqueous humor is a watery, ionic fluid, much like plasma in the blood, produced
by the ciliary body that fills the anterior chamber of the eye [89]. Unlike the vitreous
humor in the vitreous chamber of the eye, aqueous humor is constantly produced;
therefore, in order to maintain a homeostatic environment, it must be constantly
recycled out of the eye. Regulatory aqueous outflow occurs by two pathways in the
anterior chamber: the conventional pathway, comprised mainly of the TM, and the
unconventional outflow pathway, comprised of drainage channels located at the angle
between the ciliary muscle and the iris. The conventional pathway regulates upwards of
85% of the aqueous outflow that occurs in the anterior chamber [90].
TM is the major component of the conventional outflow pathway, comprised of
TM cells, juxtacanalicular connective tissue (JCT), the inner walls of Schlemm’s canal,
Schlemm’s canal, the collector channel, and finally the episcleral vein, which carries
aqueous humor back to systemic circulation [91, 92]. The TM is located at the
iridocorneal junction of the anterior chamber, the area where the iris forms a junction
with the cornea. In addition to giving the eye its shape, aqueous humor is responsible
for providing nutrients to the avascular structures of the anterior chamber, including the
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lens and cornea [89, 90]. However, one of the more important functions aqueous humor
provides to the microenvironment of the eye is producing IOP [89], which is largely
regulated by resistance of outflow provided by the TM in the conventional outflow
pathway. Studies have shown that resistance to outflow is increased with age and in
ocular disorders, such as glaucoma, where IOP elevation is a pathological hallmark
[90].
Glaucoma is a neurodegenerative protein misfolding disorder, characterized by
retinal ganglion cell (RGC) death and optic nerve (ON) axon damage leading to
progressive irreversible vision loss [31, 52-55]. Glaucoma is the second leading cause
of blindness worldwide, with over 60 million individuals suffering from the disease. In the
United States alone, it is estimated that 2-3 million people have glaucoma, with over
120,000 individuals suffering blindness due to the disease [31, 56, 77]. The most
common forms of glaucoma include open-angle glaucoma, angle-closure glaucoma,
normal-tension glaucoma, and congenital glaucoma. Although all forms of glaucoma are
seen throughout the population, over 90% of cases involve a form of POAG [32, 33]. In
POAG aqueous drainage channels remain exposed, but the TM network is damaged
preventing proper outflow [33]. POAG arising from distinct mechanisms is often
associated with accumulation of the glycoprotein myocilin, within the TM and Schlemm’s
canal [22, 24, 34, 35, 41].

4.3 Normal Intracellular Myocilin Processing
Understanding the normal features of myocilin protein could help to elucidate
why this protein accumulates in the glaucomatous eye. Myocilin is a ubiquitous 504
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amino acid (aa) secreted glycoprotein expressed in both ocular and non-ocular tissues.
In the eye, myocilin is found in the TM, sclera, ciliary body, choroid, cornea, iris, retina,
and ON [93]. Outside the eye, myocilin is expressed in tissues of the peripheral nervous
system [94]. Structurally, myocilin consists of an N-terminal region containing a signal
peptide sequence (aa 1-32), a helix-turn-helix (aa 18-58) and a leucine zipper domain
containing two coiled-coil domains (aa 74-110 and aa 118-186) responsible for
coordinating protein-protein interactions [3, 77]. Myocilin is a glycoprotein that normally
undergoes asparagine-linked glycosylation at aa residues 57–59 (Asn-Glu-Ser) [22, 95].
The C-terminal globular region contains the olfactomedin (OLF) domain (aa 230-504)
[40, 77], an evolutionarily conserved region of amino acids first discovered in the
olfactory neuroepithelium. In humans, the OLF domain is found within a group of
glycosylated proteins important in the organization of the nervous system during
development [34, 96]. Though myocilin is expressed throughout the body, its
physiological function is yet unknown. Recent studies have suggested the importance of
myocilin in oligodendrocyte differentiation and axonal myelination [97], and myocilin
may play a role in retinal cell programmed death during development [98].
The secretory pathway is responsible for synthesis, folding, and delivery of a
wide range of cellular proteins, including myocilin [84, 85]. This pathway is particularly
important in correctly coordinating the localization of newly formed proteins to specific
organelles and to the extracellular space [85]. The pathway is comprised of the rough
endoplasmic reticulum (ER), ER-exit sites, ER-to-Golgi intermediate compartment
(ERGIC), the Golgi complex, and post-Golgi carriers [84]. During ribosome synthesis of
a polypeptide, proteins that are to be secreted are targeted by a signal recognition
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particle (SRP), a molecule that targets hydrophobic peptide signal sequences on the Nterminal domain of a protein. SRPs direct the translocation of newly forming
polypeptides into the ER membrane via translocons, or channels in the ER membrane,
for continued translation and post-translational modifications required for secretion.
Once in the ER membrane, post-translational modifications such as signal peptide
cleavage, glycosylation, disulfide bond formation, and glycosidase trimming occur to
ensure proper protein folding.
The cleavage of the N-terminal signal peptide sequence is a common
modification for many proteins that enter the ER, including myocilin. Cleavage of this
sequence occurs via signal peptidase complex (SPC), a 4-subunit polypeptide. Most of
the SPC subunits are required for cell viability, except the Sec11 subunit, which
contains the protease active site [84]. The SPC cleaves off the N-terminal signal peptide
sequence, exposing glycosylation sites on the protein [84, 85]. Asparagine –linked (Nlinked glycosylation) is a post-translational modification where oligosaccharides are
attached to asparagine residues in the N-terminal domain of the protein [99].
Oligosaccharyltransferase enzyme (OST), an 8-subunit polypeptide, carries out the
addition of oligosaccharides. Cells require the majority of the OST subunits for viability,
though the Stt3 domain is dispensable and only required for catalytic activity. N-linked
glycosylation of a protein is thought to be important in thermodynamic stability,
solubility, and protein folding [99]. Glycosylated proteins in the ER membrane then form
disulfide bonds at free sulfhydryl groups on cysteine residue side chains due to the
oxidizing environment within the ER lumen. A specialized family of disulfide isomerases
is required for the formation, reduction and isomerization of these disulfide bonds,
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ensuring correct protein folding [100]. Once the signal sequence is cleaved, proteins
are glycosylated and disulfide bonds form. Following this process, the final step required
for proper protein folding is the trimming of glucose residues from the protein
oligosaccharide core. Glucosidases (Gls1/Gls2) are enzymes that rapidly trim glucose
residues, allowing for proper chaperone folding [101]. Mns1 and Htm1, enzymes that
cleave mannose residues, generate signals for protein degradation by recognizing
proteins that are terminally misfolded [102].
After post-translational modifications, proteins are exported to ER-exit sites,
areas that have a high concentration of coat-protein complex II (COPII) [85, 103]. COPII
is a molecule that forms a coat around properly folded proteins, promoting vesicle
formation for Golgi transport. COPII vesicle formation is activated by the ER GTPase
Sar1, which interacts with Sec proteins responsible for protein recruitment to form
Sec23-24 and Sec13-31 complexes. The Sec23-24 complex is vital for protein capture
and the Sec13-31complex is necessary for COPII coat formation [103, 104]. Once
COPII vesicles are formed around proteins, they can fuse with each other forming preGolgi intermediates [105], or fuse with already made ERGIC [106] and directed to the
Golgi complex (Fig. 4.1A), where they are further modified and processed, allowing
delivery to their final destination [107, 108]. Each step along this pathway represents a
potential point where myocilin processing could go awry. This entire process is
particularly relevant for understanding how a group of POAG cases that are caused by
mutations in the secreted myocilin protein.
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4.4 Myocilin Misfolding Propagates Glaucomatous Pathology
Mutations in the MYOC gene are observed in ~30% of juvenile onset glaucoma
cases, and 2-4% of patients with POAG. To date, over 70 glaucoma-causing myocilin
mutations have been identified, with >90% found in the C-terminal OLF domain [3].
Less than 10% of disease-causing mutations are located in the N-terminal domain.
Mutations in the C-terminus of the myocilin protein result in conformational changes in
the tertiary structure of the protein, namely that charged residues important for
regulating cleavage and secretion are no longer solvent-exposed [2, 33, 37, 56] (Table
4.1). These mutations thus induce a toxic gain of function for the cell via myocilin protein
misfolding and abnormal amyloidosis in the ER of TM cells [43]. Based on the genetic
evidence, it is thought that the point mutations in the MYOC gene make the protein
prone to misfolding, intracellular retention and subsequent aggregation somewhere
along the secretory pathway in TM cells. This leads to ER stress, causing TM cell death,
dysfunctional aqueous humor outflow, increased IOP and eventually optic nerve
damage [22, 35, 37].
In addition to inherited mutations in myocilin, inhibition of post-translational
modifications in WT myocilin can alter secretion leading to intracellular accumulation.
Our laboratory examined this phenomenon by utilizing two pharmacological inhibitors,
tunicamycin and brefeldin a. Tunicamycin is a well-documented inhibitor of N-linked
glycosylation, leading to improper protein folding; Brefeldin A is an inhibitor of ER-Golgi
transport. Treatment of cells overexpressing WT myocilin with Tunicamycin or Brefeldin
A resulted in increased levels of intracellular myocilin [43]. Moreover, prolonged
treatment with glucocorticoids can result in increased myocilin deposition within the ER
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of TM cells, which has been documented to cause glaucoma pathology in humans [109111]. We have shown that WT myocilin, similar to other secreted proteins, is typically
degraded through the proteasomal-dependent ER-associated degradation (ERAD)
mechanism (Fig. 4.1b) [43, 84, 85]. ERAD is a process that uses the VCP/p97 complex
to typically triage misfolded proteins from the ER lumen to the cytosol for ubiquitination
and subsequent proteasomal degradation [112]. But in cases where misfolded myocilin
is produced, either by mutation or altered post-translational modification, this clearance
mechanism fails, leading to myocilin aggregation, ER stress and TM cell toxicity.
Therefore, if ERAD could be restored for these misfolded myocilin species, or another
clearance mechanism could be engaged, such as autophagy, myocilin toxicity in the TM
could be reduced.

4.5 Autophagic Degradation of Misfolded Proteins Promotes Cellular
Homeostasis
Even in normally functioning cells, if there is a proteotoxic stress leading to
accumulation of misfolded proteins in the ER, the unfolded protein response (UPR) is
activated. If the activation is acute, then the UPR is beneficial to the cell, but if the
activation is chronic, it can facilitate cell death [86, 113, 114]. In cases of glaucoma
caused by mutations in the MYOC gene, the UPR seems to be chronically activated,
suggesting that this could be a primary mechanism of TM cell death. While trying to
stimulate ERAD of mutant myocilin is one approach for overcoming chronic UPR
activation, one caveat of this mechanism is that ubiquitin-proteasome degradation is
limited to monomeric proteins. For an amyloidogenic protein like myocilin, this simply
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may never work. When the cell needs to degrade damaged organelles or aggregated
proteins, a less specific but more robust ER autophagic mechanism of clearance
(reticulophagy) is available. Engaging this system may be much more efficient for
facilitating removal of myocilin aggregates from the ER [115].
Autophagy is a general term used for the process involving degradation by
lysosome-containing vesicles. There are at least three types of autophagy, differing by
their means of delivering material to the lysosome for degradation: macroautophagy,
microautophagy, and chaperone-mediated autophagy [116, 117]. During chaperonemediated autophagy, substrates are recognized by a particular amino acid peptide
sequence and are translocated into the lumen of a lysosome for degradation [28].
Microautophagy is a less specific process where the lysosomal membrane invaginates
or sequesters material in the cytosol for degradation within the lysosome [118]. In
addition, organelles such as the mitochondria and the ER can degrade their protein
content via distinct routes that ultimately utilize macroautophagy [119].
Macroautophagy is a catabolic process necessary for cell homeostasis [53, 117,
120]. It is upregulated when cells require intracellular nutrients and energy such as
during starvation, growth factor withdrawal, or in the context of high-energy demand
[95]. Additionally, macroautophagy can be upregulated in times of cellular proteotoxic
stress, when misfolded proteins accumulate. Macroautophagy is a multi-step process
consisting of four stages: initiation, nucleation, maturation, and degradation. Initiation
occurs by the down-regulation of the mammalian target of rapamycin (mTOR) pathway
[116]. In times of starvation autophagy-related protein 13 (Atg13) and unc51-like
autophagy activating kinase (Ulk1/2) are upregulated leading to the inhibition of the
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mTOR pathway. Conversely, when growth factors, such as insulin-like growth factor,
bind to growth factor receptors, initiation of receptor tyrosine kinase signaling and
subsequent activation of protein kinase B (AKT) occurs. AKT activation inhibits the
major inhibitory proteins of the mTOR pathway, tuberous sclerosis 1 and 2 (TSC1/2),
resulting in the activation of the mTOR pathway and subsequent inhibition of
macroautophagy [121]. Additionally, mTOR inhibition leads to ULK1 phosphorylation
and activation of autophagic effectors Beclin1 and phosphatidylinositol 3-kinase (Vps34)
[95].
Following initiation, nucleation is the process in which the autophagosome, the
unique organelle associated with macroautophagy, forms. Phosphorylated
Beclin1/Vps34, along with p150, form a stable complex that initiates formation of the,
pre-autophagosome, or phagophore [121]. The phagophore matures into the
autophagosome and fully surrounds the target cytosolic components. This process
involves the elongation of the phagophore membrane via the incorporation of
microtubule-associated protein 1A/1B-light chain 3 (LC3) into the membrane. LC3
mediates autophagosome growth and cytoplasmic cargo recruitment, and provides a
scaffold to transport fully formed autophagosomes to the lysosomes. Once the
autophagosome has fully formed around cytoplasmic constituents, LC3 mediates
dynein-dependent microtubule trafficking to lysosomes. Finally, the autophagosome
fuses with the lysosome via the SNARE proteins VAMP8, Vti1B, and Lamp2, and
results in the formation of the autolysosome. Following autolysosome formation, the
autophagic cargo is degraded and then recycled back to the cytosol for cell re-uptake
[95, 121].
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Until recently macroautophagy was thought of as a non-selective degradation
pathway, but current research has proposed the idea of organelle-specific autophagy,
including ribophagy (ribosomes), mitophagy (mitochondria) and reticulophagy (ER).
While specific details on individual organelle autophagy remain largely uncharacterized,
it is postulated that cellular constituents are targeted for these distinct autophagic
pathways by Atg upregulation leading to autophagosome formation or possibly by
accumulation of intra-ER ubiquitinated proteins [119]. The latter is supported by work
from our laboratory showing that only mutant/misfolded myocilin becomes ubiquitinated
within the ER following treatment with epoxomicin, a proteasome inhibitor [43]. In this
way, the accumulation of misfolded, ubiquitinated myocilin could activate reticulophagic
degradation.

4.6 TM Autophagic Dysregulation Promotes Ocular Disorders
Studies have shown that increasing macroautophagy can delay the aging
process, and extend tissue longevity. This was first observed in the C.elegans model,
where inhibition of the insulin-like growth factor receptor induced autophagy [122].
Conversely, mutation of Atg genes resulted in decreased tissue longevity [122].
Moreover, age-related reductions in Beclin1 [123], Sirtuin1 (A modulator of mTOR
inhibition)[124], and Atg5/7 [125] protein levels have been observed in aged tissue.
Additionally, decreased levels of ULK1 and LC3 have been observed in aged tissue. As
glaucoma is a slowly progressing ocular disorder and pathology increases are
associated with aging, it is possible this could largely be an effect of reduced autophagic
protein clearance in TM cells.
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Studies in primary human TM (hTM) cells have also shown that during glaucoma,
the autophagic mechanism in TM cells is dysregulated. Recent research has indicated a
dysregulation of the autophagic pathway and reduction of the autophagic response to
oxidative stress in TM cells isolated from patients with glaucoma [53]. Interestingly, this
research determined an overall reduction of LC3 in TM cells of glaucoma patients
compared to controls [53]. Additionally, there was an increase in senescenceassociated-β-galactosidase (SA-β-Gal) activity, which is shown to be upregulated when
autophagy is inhibited in primary human fibroblasts [126]. Moreover, they observed an
increase in lipofuscin, or non-degradable lysosomal content, in TM cells of glaucoma
patients compared to control cells [53]. Other proteins associated with autophagy found
to be down regulated during glaucoma were sequestosome-1 (p62), a scaffold that
targets ubiquitinated proteins for autophagic degradation, scCTSB, a lysosomal protein,
and LC3B-II [53]. Taken together, these data show that autophagic clearance
mechanisms are dysfunctional in TM tissue of glaucoma patients. Thus, restoring these
pathways could be beneficial in disease.

4.7 Grp94 Prevents Misfolded Myocilin Degradation via Autophagy
ER homeostasis, including ERAD and reticulophagy pathways, is mediated by
chaperone activity. Chaperones aid in the proper folding of proteins under physiological
conditions as well as in times of ER stress [28, 127, 128]. Stress caused by
accumulation of terminally misfolded proteins activates the UPR, resulting in cessation
of protein translation [113, 127] and increased production of molecular chaperones
[114]. We recently performed a small-interfering RNA (siRNA) screen on several ER76

associated chaperones to examine their effects on overexpressed I477N mutant
myocilin or WT myocilin in Hek293T cells [43]. Interestingly, only knockdown of glucoseregulated protein 94 (Grp94), the ER-specific isoform of Hsp90, caused intracellular
I477N mutant myocilin reduction. Under physiological conditions, Grp94 is inactive
[129]. During ER stress, Grp94 is associated with ER quality control and aids in the
proper folding of misfolded proteins. Grp94 also associates with the ERAD-associated
osteosarcoma amplified 9 (OS-9) protein and acts to shuttle terminally misfolded
monomeric protein to the ER membrane for subsequent proteasomal degradation [129,
130]
This intracellular reduction was also observed in cells overexpressing four other
common glaucoma-associated myocilin mutations [54]. Interestingly, Grp94 knockdown
had no effect on intracellular or secreted levels of WT myocilin. Moreover, following
myocilin immunoprecipitation (IP), we found that Grp94 associated with mutant protein
but not WT myocilin [43], highlighting the specificity offered by this chaperone. Using a
cycloheximide (a potent inhibitor of protein translation) chase experiment, we were able
to determine that the half-life of intracellular mutant myocilin was decreased after Grp94
inhibition. Additionally, we observed an increase in high-molecular weight myocilin
species with Grp94 overexpression, and conversely, reduction in high-molecular weight
myocilin species after Grp94 knockdown [43]. This led us to believe that Grp94 was
preserving mutant myocilin, and possibly driving protein aggregation.
Importantly, Grp94 inhibition also reduced intracellular mutant myocilin levels, as
well as cellular toxicity associated with mutant myocilin overexpression, in primary hTMs
[54]. Interestingly, Grp94 inhibition had no effect on normally folded WT myocilin levels.
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However, when N-linked glycosylation of WT myocilin was blocked by tunicamycin, we
observed an increased association with WT myocilin and Grp94. This was accompanied
by sensitization to Grp94 inhibition [43]. Moreover, Grp94 could stimulate aggregation of
WT myocilin OLFs in vitro, a process that could be mitigated by the addition of Grp94
inhibitor [54]. These data led us to the conclusion that Grp94 recognizes misfolded
myocilin species within the ER, but iteratively attempts to triage the protein through
ERAD unsuccessfully. This leads to myocilin protein aggregation in the ER and
subsequent TM cell toxicity (Fig. 4.2).
To explore the feasibility of Grp94 inhibition as a potential therapeutic
mechanism, one first must examine the importance of Grp94 in an organism. Grp94, as
a molecular chaperone of the ER, has relatively few client proteins [44]. Interestingly,
despite this Grp94 is necessary for embryonic development. This has been shown in
studies looking at both heterozygous (+/-) and homozygous (-/-) knockdown of Grp94 in
murine models and of gp93 in drosophila [131]. While the -/- mice have lethality and a
number of other functional deficits, +/- mice survive and seem healthy, suggesting that
partial but not complete depletion of Grp94 may be a viable therapeutic strategy [132].
Moreover, recent studies have shown that targeted knockout in discreet tissues does
not impact viability [86]. However, Grp94 does play important roles in immune cell and
liver function [133, 134], and others, suggesting that caution will be necessary moving
forward with therapeutic approaches targeting this protein.
While previous data suggests that the inhibition of Grp94 association with
misfolded or mutant myocilin leads to intracellular degradation of the myocilin protein
and therefore could be a potential therapeutic target to treat glaucoma, the mechanism
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by which degradation of this protein occurs was still not known. To determine if the
autophagic pathway was involved in misfolded myocilin protein clearance, cells
overexpressing mutant myocilin (I477N) were co-transfected with Grp94 siRNA and
either Lamp2 or Beclin1 siRNA, two well-characterized components of the autophagy
pathway. Indeed the addition of Lamp2 or Beclin1 siRNA abrogated intracellular
myocilin clearance following Grp94 knockdown [43]. Thus, inhibiting Grp94 shunts
misfolded myocilin towards the autophagic degradation pathway, a pathway that must
be functional for mutant myocilin turnover (Fig. 4.3). In fact, since TM cell dysfunction
prevents normal aqueous humor outflow, nutrient delivery to these cells is impaired,
which would normally trigger macroautophagy and possibly facilitate misfolded myocilin
clearance, restoring balance to the outflow pathway. But, because of the interaction of
Grp94 with myocilin, its autophagic degradation is prevented, allowing glaucomatous
pathology to perpetuate. Therefore, discovering therapeutic measures to enhance the
ER autophagic mechanism, allowing for misfolded myocilin to be degraded, could lead
to restoration of TM cell function and reduction in glaucomatous pathology. In fact,
perhaps combining Grp94 inhibition with enhancers of reticulophagy could work
together synergistically to promote myocilin clearance and rescue glaucoma caused by
myocilin toxicity.
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Table 4.1 List of known mutations in the MYOC gene that lead to glaucoma. Bold
denotes mutations in the N-terminus; Underline denotes mutations in the C-terminus.
Mutation (AA)
C25R
R46X
R82C
R91X
R126W
C245Y
G246R
V251A
G252R
R272G
P274R
W286R
T293K
E300K
S313F
E323K
Q337R
R342K
I345M
Y347X
I360N
P361S
A363T
G364V
G367R
Q368X
P370L
T377M
D380G
D380H
D380N
D380A
S393N
S393R
K423E
V426F
A427T
C433R
Y437H
A445V
T448P
N450D
Y453del
I465M
R470C
Y471C
I477N
I477S
N480K
P481S
P481T
P481R
E483X
I499F
S502P

Gene Location
Exon1
Exon1
Exon1
Exon1
Exon1
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3
Exon 3

Ref
[33]
[2]
[4] [2]
[135]
[136]
[7]
[56]
[137]
[56]
[56]
[138]
[2]
[2]
[135]
[139]
[56]
[56]
[140]
[137]
[2]
[141]
[2]
[141]
[2]
[142]
[2]
[56]
[2] [142]
[13]
[13]
[13]
[56]
[137]
[2]
[56]
[56]
[8]
[143]
[2]
[2]
[56]
[137]
[2]
[2]
[2]
[135]
[2]
[56]
[56]
[2]
[2]
[2]
[2]
[56]
[56]
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Figure 4.1 Normal intracellular processing of myocilin. After signal recognition
particle (SRP) targeting and translocation of a newly forming myocilin polypeptide to the
endoplasmic reticulum lumen, posttranslational modifications occur to ensure proper
folding of the protein. If these modifications are successful (A), the newly formed,
properly folded, protein will be sent to the Golgi apparatus via COPII coat formation for
packaging and delivery to specific cellular organelles or the extracellular space.
However, if these modifications do not properly occur (B), and the protein becomes
terminally misfolded, the intra-ER degradation mechanism, known as ERAD, will
degrade the protein through a proteaosomal dependent manner for peptide recycling.
This method requires the ubiquitination of misfolded proteins, and is only substantial if
the misfolded protein is monomeric.
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Figure 4.2 Grp94 association with mutant myocilin promotes intracellular
accumulation. Mutations in the MYOC gene lead to the production of myocilin protein
that readily misfolds and is prone to aggregation. Grp94 is an ER-associated cochaperone that recognizes pre-aggregated misfolded myocilin, preventing ERAD
proteasomal degradation, leading to aggregation within the ER. Proteotoxicity caused
by aggregated myocilin in the ER leads to TM cell death and aqueous outflow
dysfunction, promoting the pathologies associated with glaucoma.
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Figure 4.3 Inhibition of Grp94 interaction with mutant myocilin promotes
autophagic degradation. Through siRNA knockdown or pharmacological inhibition,
Grp94 association with misfolded myocilin can be prevented, inhibiting protein
aggregation. After inhibition, misfolded myocilin can be processed into transport
vesicles for transport out of the ER lumen to the cell cytosol, where these vesicles fuse
with lysosomes promoting autophagic degradation of the misfolded protein. As
aggregated misfolded myocilin is cleared form the ER of TM cells, aqueous outflow
becomes restored.
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Chapter Five:
Final Considerations
This study has demonstrated that intra-ER misfolded myocilin mechanics can be
altered by the chaperone, Grp94. Specifically, Grp94 recognition of terminally misfolded
myocilin prevents ERAD clearance promoting protein accumulation precipitating cellular
toxicity. Through pharmacological inhibition, misfolded myocilin clearance and
degradation can occur, albeit through the robust autophagic pathway. The major
findings of this study demonstrate how the alteration of Grp94 interaction with mutant
myocilin can lead to 1) reduced intracellular myocilin accumulation, 2) reduced TM
cellular toxicity, 3) promotion of the autophagic clearance mechanism, and 4)
pathological rescue of glaucoma phenotypes. We have clearly shown that Grp94
association with misfolded myocilin in the ER of TM cells is a major contributor to
myocilin accumulation causing glaucomatous pathologies. This study supports the
possibility of developing novel therapeutics inhibiting Grp94’s association with misfolded
myocilin as a viable treatment option for POAG.
For quite some time, chaperone modulation has been a therapeutic target for
multiple diseases including, Alzheimer’s disease [66, 144], Parkinson’s disease [145,
146], and Cancer [78, 147]. Specifically, Grp94 inhibition has been previously studied as
a potential target for cancer treatment [44, 148]. However, until our work outlined in this
manuscript, Grp94 was not considered a target for potential glaucoma treatment. In fact,
until our work, Grp94 was not known to be associated with myocilin in cases of myocilinassociated glaucoma. With our previously discussed work, we have clearly shown the
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importance of Grp94 associating in progressing myocilin-associated glaucoma
pathology, as well as discovered a novel target for therapeutic intervention. Moreover,
we have shown that topical administration of a Grp94 inhibitor can alleviate pathologies
associated with myocilin-induced glaucoma. Development of new Grp94 inhibitors that
are more potent at lower concentrations, as well as have greater anterior chamber
bioavailability when applied topically, would be vital in progressing this research forward
into higher organisms, including humans. These studies support the idea of specific
therapeutic intervention targeting the underlying glaucoma disease mechanism as a
viable means for not only reducing symptoms, but curing the disease all together.
Clear limitations arise in our approach as currently the underlying disease
mechanism of glaucoma is still unknown. While our research has shown a direct link to
Grp94 association with misfolded myocilin as a mediating factor of myocilin
accumulation and toxicity, the specific disease mechanism must be discovered to fully
understand potential therapeutic targets. Additionally, while topical administration of
ophthalmic drugs continue to be the gold standard in treating various ailments of the
eye, more direct drug delivery may be necessary to reduce unwanted off target effects.
Previous clinical trials studying the effects of Hsp90 modulation in the treatment of
cancer and other diseases have shown promise, however, off-site toxicities have
prevented research from advancing [44]. Additionally, while a majority of glaucoma
research centers on myocilin accumulation in the ER of TM cells, the biological
relevance of myocilin in the human body still remains unknown. While groups have
postulated myocilin’s importance in cell proliferation, peripheral axon myelination,
oligodendrocyte differentiation, and optic nerve myelination, its specific function remains
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relatively unknown [94, 97, 149]. Therefore, specifically targeting accumulated myocilin
in the ER of TM cells would be necessary to prevent off-target toxicities from systemic
or broad administration.
Finally, while we have shown promising results in targeting Grp94 as a means for
reducing POAG pathology, other forms of glaucoma, including closed-angle and steroid
induced glaucoma, remain without a viable curative treatment option. Next steps in our
research will center on determining to what extent, if any, myocilin accumulation plays in
the development of other subtypes of glaucoma. Determining if myocilin is directly
responsible for multiple glaucoma subtypes would allow us to progress our research,
determining if Grp94 inhibition is a viable treatment method for all glaucomas.
Additionally, determining the specific mechanism of misfolded myocilin degradation
following Grp94 inhibition would be imperative in advancing this work into clinical trials.
While we have shown evidence linking autophagic degradation to misfolded myocilin
clearance, the specific mechanism, and proteins involved are still unknown. Determining
the specific mechanism of degradation could also lead to new targets for potential
therapeutics. While this research is still in its infancy, promising results could lead to the
first curative therapeutic for treating POAG.
Overall our findings suggest there is a direct relationship between Grp94 and
misfolded myocilin, which leads to pathologies associated with POAG. Through specific
pharmacological inhibition, we were able to alleviate myocilin-associated glaucoma
pathology, while promoting misfolded myocilin clearance. This work validates Grp94 as
a potential therapeutic target for treatment of myocilin-associated POAG.
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